



**ANNUAL
REPORT
2016 / 2017**

MEDIC  **SKIN**

MEDICSKIN HOLDINGS LIMITED

密迪斯肌控股有限公司

(Incorporated in the Cayman Islands with limited liability)

STOCK CODE : 8307

CHARACTERISTICS OF THE GROWTH ENTERPRISE MARKET (“GEM”) OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE “STOCK EXCHANGE”)

GEM has been positioned as a market designed to accommodate companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration. The greater risk profile and other characteristics of GEM mean that it is a market more suited to professional and other sophisticated investors.

Given the emerging nature of companies listed on GEM, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board of the Stock Exchange and no assurance is given that there will be a liquid market in the securities traded on GEM.

Hong Kong Exchanges and Clearing Limited and the Stock Exchange take no responsibility for the contents of this report, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this report.

*This report, for which the directors (the “**Directors**”) of Medicskin Holdings Limited (the “**Company**”) collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the GEM of the Stock Exchange (the “**GEM Listing Rules**”) for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this report is accurate and complete in all material respects and not misleading or deceptive; there are no other matters the omission of which would make any statement herein or this report misleading.*

CONTENTS

Corporate Information	2
Chairman's Statement	3-4
Management Discussion and Analysis	5-12
Report of the Directors	13-25
Corporate Governance Report	26-34
Environmental, Social and Governance Report	35-41
Biographical Details of Directors and Senior Management	42-44
Independent Auditor's Report	45-48
Consolidated Statement of Profit or Loss and Other Comprehensive Income	49
Consolidated Statement of Financial Position	50-51
Consolidated Statement of Changes in Equity	52
Consolidated Statement of Cash Flows	53-54
Notes to the Consolidated Financial Statements	55-90
Financial Summary	91

CORPORATE INFORMATION

BOARD OF DIRECTORS

Executive Directors

Dr. Kong Kwok Leung (*Chairman*)
Mr. Lo Kwok Bun (*Chief Executive Officer*)
Ms. Kong Chung Wai
Ms. Sin Chui Pik Christine

Independent Non-executive Directors

Mr. Chan Cheong Tat
Mr. Lee Ka Lun
Mr. Leung Siu Cheung

BOARD COMMITTEES

Audit Committee

Mr. Chan Cheong Tat (*Chairman*)
Mr. Lee Ka Lun
Mr. Leung Siu Cheung

Remuneration Committee

Mr. Leung Siu Cheung (*Chairman*)
Dr. Kong Kwok Leung
Mr. Lo Kwok Bun
Mr. Chan Cheong Tat
Mr. Lee Ka Lun

Nomination Committee

Dr. Kong Kwok Leung (*Chairman*)
Ms. Kong Chung Wai
Mr. Chan Cheong Tat
Mr. Lee Ka Lun
Mr. Leung Siu Cheung

COMPLIANCE OFFICER

Ms. Kong Chung Wai

COMPANY SECRETARY

Ms. Sin Chui Pik Christine *CPA, FCCA*

AUTHORISED REPRESENTATIVES

Ms. Kong Chung Wai
Ms. Sin Chui Pik Christine

HONG KONG LEGAL ADVISER

Howse Williams Bowers
27th Floor, Alexandra House
18 Chater Road
Central
Hong Kong

PRINCIPAL BANKERS

Hang Seng Bank Limited
83 Des Voeux Road Central
Hong Kong

The Hongkong and Shanghai Banking Corporation Limited
1 Queen's Road Central
Hong Kong

REGISTERED OFFICE

P.O. Box 309
Ugland House
Grand Cayman, KY1-1104
Cayman Islands

HEADQUARTER AND PRINCIPAL PLACE OF BUSINESS IN HONG KONG

21st Floor, New World Tower II
16-18 Queen's Road Central
Hong Kong

PRINCIPAL SHARE REGISTRAR AND TRANSFER OFFICE

Maples Fund Services (Cayman) Limited
P.O. Box 1093, Boundary Hall
Cricket Square
Grand Cayman, KY1-1102
Cayman Islands

HONG KONG BRANCH SHARE REGISTRAR AND TRANSFER OFFICE

Tricor Investor Services Limited
Level 22, Hopewell Centre
183 Queen's Road East
Hong Kong

AUDITOR

Deloitte Touche Tohmatsu
35/F, One Pacific Place
88 Queensway
Hong Kong

COMPLIANCE ADVISER

Ample Capital Limited
Unit A, 14th Floor
Two Chinachem Plaza
135 Des Voeux Road Central
Hong Kong

COMPANY WEBSITE

www.medicskin.com

GEM STOCK CODE

8307

CHAIRMAN'S STATEMENT

Dear Shareholders,

On behalf of the board of Directors (the "**Board**") of the Company, it is my pleasure to present this annual report and the audited consolidated financial statements of the Company and its subsidiaries (collectively referred to as the "**Group**") for the year ended 31 March 2017 to you.

A YEAR IN REVIEW

In 2016, the Hong Kong retail market remained weak and volatile during the year as a result of slowdown in the economic growth of China and Hong Kong, political uncertainties, volatility of equity markets and strong position of US dollar. The sales momentum and customer spending sentiment in Hong Kong was adversely affected. It was not an easy year for service providers in Hong Kong. In addition, the Group continued to face a very high operating costs base from rental expenses and staff costs as well as intense competition in the industry. As one of the medical skin care service providers in Hong Kong, our business was inevitably affected. Nevertheless, the Group, as one of the pioneers in the medical skin care industry in Hong Kong, would make the best use of our advantages and continue to seek opportunities to grow.

Despite the challenging market conditions, the Group improved its performance in the second half of the year with growth in revenue and notable increase in net profit. During the year under review, revenue of the Group amounted to HK\$62.1 million, representing an increase of 3.3% from HK\$60.1 million of last corresponding year.

- The Group's profit before interest, tax, depreciation and amortisation ("**EBITDA**") increased by 29.8% from HK\$5.7 million of last corresponding year to HK\$7.4 million.
- The Group's adjusted net profit attributable to the shareholders of the Company (the "**Shareholder(s)**") (excluding one-off extra rental expenses and ancillary costs of premises paid during the renovation period of the new skin care centre branded "Medicskin" (the "**Medicskin Centre(s)**") in Central of HK\$0.9 million) increased by 57.7% from HK\$2.6 million of last corresponding year to HK\$4.1 million.
- The Group's unadjusted net profit attributable to the Shareholders increased 33.3% from HK\$2.4 million of last corresponding year to HK\$3.2 million.

Basic earnings per share for the year was HK0.73 cent as compared to HK0.59 cent per share of last corresponding year.

We devoted ourselves to implement the plans as planned to provide professional, reliable and convenient services to clients. During the year under review, the Group relocated its Central Medicskin Centre from Tak Shing House to New World Tower II, which occupies the whole 21st floor of New World Tower II, with around 5,000 square feet in gross floor area. The new Central Medicskin Centre was opened in May 2016, with elegant décor which provides better facilities and a more comfortable environment to our clients, enhancing our clients' experiences. We believe this in turn will enhance clients' satisfaction and in long term bring additional revenue to the Group.

We are pleased to introduce that following the subscription of shares of the Company (the "**Subscription**") for HK\$51.8 million on 25 October 2016, our new strategic Shareholder, Fullshare Holdings Limited ("**Fullshare**") whose issued shares are listed on the Stock Exchange (stock code: 607), has taken up 16.65% shareholding of the Company and became a substantial Shareholder. We consider that, the Subscription broadened the Shareholder base of the Company and brought in a renowned investor with strong financial resources and extensive business network, which in turn would bring strategic value to the Group as well as provide synergy to the Group in the development of its business in the medical skin care industry.

CHAIRMAN'S STATEMENT

Having considered the continuous strong demand from both users and investors of office buildings in prime locations in Hong Kong, we considered that it would be in the long term interests of the Company and its Shareholders to have its Medicskin Centres operating in self-owned properties. We acquired a property located in Causeway Bay and the acquisition has been completed in March 2017. The new acquired property occupies a total gross floor area of approximately 3,200 square feet. Upon expiration of the lease of property in February 2018, the property will be used as a new skin care centre of the Group.

To reward the Shareholders, the Board is pleased to recommend a final cash dividend of HK0.2 cent per ordinary share of the Company ("**Share**") for the year ended 31 March 2017 and represented about 31.3% of the Group's net profit attributable to the Shareholders.

OUTLOOK

Looking forward to 2017, it is expected that the retail environment of Hong Kong market will remain sluggish with strong local currency and anticipated interest rate rise and the competition in the medical skin care industry will remain intense. Nevertheless, with the growing emphasis on a person's physical appearance in the society and increasing demand for medical skin care services, we are still prudently optimistic about the Group's performance in the future.

The government of Hong Kong has been considering to tighten up the regulation of the beauty industry and released the Consultation Report on Regulation of Private Healthcare Facilities ("**PHFs**") in April 2016 and will revamp the regulatory regime for PHFs through legislation to strengthen regulation and enhance standards, aiming to protect patients' safety and consumer rights as well as contribute to the sustainable development of the local healthcare system. Such proposed legislation may introduce a change in compliance standards in connection with delivery of treatments, and ultimately bring higher level of confidence to customers, enhance the level of safety in the industry and increase the total spending in the market.

We believe the Group has successfully established a reputation for being a trustworthy, reliable and quality provider of skin care services. We attribute our success to our professionalism in the delivery of services, which includes making safety and well-being of our clients as priority. To cope with the challenges ahead, the Group will continue concentrate on exploring and launching new types of services and products that we offer; growing the presence of our existing business and identifying new business opportunities, in order to deliver value to both our clients and our Shareholders.

APPRECIATION

On behalf of the Board, I wish to take this opportunity to express my sincere gratitude to the Shareholders, business partners, suppliers and clients for their continued support to the Group. I would also like to express my heartfelt appreciation to the management and the staff for their diligence and valuable contribution throughout the year. In the future, we will thrive continuously to expand our business and use our best endeavor to provide the highest quality medical skin care services.

Dr. Kong Kwok Leung

Chairman

Hong Kong, 16 June 2017

MANAGEMENT DISCUSSION AND ANALYSIS

BUSINESS REVIEW

The Group is a medical skin care group operating two medical skin care centres branded “Medicskin” (“**Medicskin Centres**”) at prime locations in Hong Kong that primarily focus on the treatment of skin diseases and problems and/or the improvement of appearance of clients. The Group provides services to clients for the treatment of, inter alia, skin diseases and problems such as acne, pigmentation, rosacea, dermatitis, eczema and warts, as well as for the improvement of appearance through, inter alia, skin rejuvenation, facial sculpturing and body contouring treatments, treatments of acne scars and enlarged pores, removal of undesirable naevi, and hair removal.

In 2016, the Hong Kong retail market remained weak and volatile during the year. As revealed by the Census and Statistics Department of Hong Kong, the total retail sales value in 2016 in Hong Kong fell by 8.1% to HK\$436.6 million compared with that of 2015. Despite the challenging market conditions, the Group improved its performance in the second half of the year with growth in revenue and notable increase in net profit.

For the year ended 31 March 2017, the revenue of the Group increased by approximately HK\$2.0 million, or 3.3%, to approximately HK\$62.1 million, when compared to the year ended 31 March 2016. The revenue of consultation service, prescription and dispensing service and treatment service amounted to approximately HK\$3.8 million, HK\$24.6 million and HK\$33.7 million which accounted for approximately 6.1%, 39.6%, and 54.3% of the total revenue of the Group respectively. More than half of the Group’s revenue was derived from treatment service, which typically involves the injection of Botulinum Toxin Type A and hyaluronic acid, cauterisation, and treatments with the use of devices deploying technologies such as laser, radiofrequency and intense focused ultrasound. The increase in revenue was primarily attributable to the increase in the number of client visits and average revenue (per visit) from treatment service. Approximately 74.0% of our clients were aged between 26 to 55, while approximately 89.0% of our clients were female. Most of the treatment service was performed by our doctors, with approximately 94.9% of the revenue from treatment service generated from treatments performed by our doctors at our Medicskin Centres. The Group’s net profit attributable to the Shareholders increased 33.3% from HK\$2.4 million of last corresponding year to HK\$3.2 million. Basic earnings per Share for the year was HK0.73 cent as compared to HK0.59 cent per Share of last corresponding year.

In May 2016, the Group’s Medicskin Centre in Central was relocated from Tak Shing House to New World Tower II, which occupies the whole 21st floor of New World Tower II, with around 5,000 square feet in gross floor area. The new Central Medicskin Centre with elegant décor provides better facilities and a more comfortable environment to our clients and enhances their experience. We believe this in turn will enhance our clients’ satisfaction and bring additional revenue to the Group in the long term.

On 29 September 2016, a subscription agreement was entered into between the Company and Rich Unicorn Holdings Limited (“**Rich Unicorn**”), pursuant to which the Company has conditionally agreed to allot and issue, and Rich Unicorn has conditionally agreed to subscribe for, 80,000,000 new Shares (the “**Subscription Shares**”) at the subscription price of HK\$0.648 per Subscription Share (the “**Subscription**”). Rich Unicorn is beneficially owned by Fullshare. The completion of the Subscription took place on 25 October 2016. The gross proceeds from the Subscription were approximately HK\$51.8 million and the net proceeds from the Subscription, after deduction of actual related expenses of approximately HK\$1.6 million were approximately HK\$50.2 million. The Board considers that, the Subscription broadened the Shareholder base of the Company and brought in a renowned investor with strong financial resources and extensive business network, which in turn would bring strategic value to the Group as well as provide synergy to the Group in the development of its business in the medical skin care industry.

MANAGEMENT DISCUSSION AND ANALYSIS

To expand the Group's service centre network in Hong Kong, Golden Dickson (HK) Limited ("**Golden Dickson**"), a wholly-owned subsidiary of the Company, entered into a provisional sale and purchase agreement with the vendor to acquire a property located at the whole of 25th floor (which includes units A, B, C and D of 25th floor), Guangdong Tours Centre, 18 Pennington Street, Hong Kong (the "**Property**") at a total consideration of HK\$44.0 million, on 24 January 2017. The formal sale and purchase agreement was signed by Golden Dickson and the vendor on 7 February 2017. The completion of the acquisition took place on 24 March 2017. Upon expiration of the existing lease of the Property in February 2018, the Property will be used as a new skin care centre of the Group. Due to the continue increase in rent of office buildings in prime locations in Hong Kong, we considered that it would be in the long term interests of the Company and its Shareholders to have its skin care centre operating in self-owned properties, and ultimately increase market penetration of the Group.

OUTLOOK

With strong local currency and anticipated interest rate rise, the weak market condition in Hong Kong is expected to persist in the coming year. It is expected that the Group will continue face very high operating costs base from rental expenses and staff costs as well as intense competition in the industry.

The proposed legislation by the government of Hong Kong to strengthen regulation and enhance standards, aiming to protect patients' safety and consumer rights as well as contribute to the sustainable development of the local healthcare system may introduce a change in compliance standards in connection with delivery of treatments, and ultimately bring higher level of confidence to customers, enhance the level of safety in the industry and increase the total spending in the market.

The Group will continue to keep abreast of the latest industry knowledge in order to offer the most suitable and updated services to our clients. The Group continuously performs market research on the development of, and evaluate the effects of the latest products, skills and treatment devices and technology. We believe that the introduction of new types of services and products is one of the driving forces for the growth of the Group's business and is a significant way to maintain the Group's competitiveness and its forefront position in the industry. We also believe the new skin care centre to be opened in Causeway Bay would attract new clients and ultimately increase market penetration and profitability of the Group.

Leveraging the support of the capital market, our own strengths, and person's pursuing on physical appearance, the Group is cautiously confident about its development in the future. We will continue using its best endeavors to provide the highest quality medical skin care services and products to our clients and strengthening its market position so as to grow its brand and business and to maximise returns for our investors.

MANAGEMENT DISCUSSION AND ANALYSIS

FINANCIAL REVIEW

Revenue

The Group's revenue increased by approximately HK\$2.0 million, or 3.3%, from approximately HK\$60.1 million for the year ended 31 March 2016 to approximately HK\$62.1 million for the year ended 31 March 2017. The increase was primarily attributable to the increase in the number of client visits and average revenue (per visit) from treatment service.

Inventories used

The Group's cost of inventories used was approximately HK\$8.3 million and approximately HK\$7.7 million for the years ended 31 March 2017 and 2016 respectively, representing 13.4% and 12.8% of the revenue for the respective years.

Staff costs

Staff costs decreased by approximately HK\$1.6 million, or 4.9%, from approximately HK\$32.7 million for the year ended 31 March 2016 to approximately HK\$31.1 million for the year ended 31 March 2017. The decrease was primarily attributable to the decrease in the number of staff.

Depreciation of property, plant and equipment

Depreciation expenses increased by approximately HK\$1.1 million or 55.0%, from approximately HK\$2.0 million for the year ended 31 March 2016 to approximately HK\$3.1 million for the year ended 31 March 2017. The increase was primarily attributable to the purchases of property, plant and equipment due to relocation of the Central Medicskin Centre during the year ended 31 March 2017.

Other expenses

Other expenses increased by approximately HK\$2.0 million, or 14.9%, from approximately HK\$13.4 million for the year ended 31 March 2016 to approximately HK\$15.4 million for the year ended 31 March 2017. The increase was primarily attributable to the increase in rental expenses and ancillary costs of premises (including management fee, air conditioning charges and government rates) and extra rental expenses and ancillary costs of premises paid during the renovation period due to the relocation of the Central Medicskin Centre.

Income tax expense

Income tax expense decreased by approximately HK\$0.1 million, or 7.7%, from approximately HK\$1.3 million for the year ended 31 March 2016 to approximately HK\$1.2 million for the year ended 31 March 2017. The decrease was primarily attributable to the decrease in profit before tax of a major operating subsidiary.

MANAGEMENT DISCUSSION AND ANALYSIS

Profit for the year

As a result of the foregoing, the profit for the year increased by approximately HK\$0.8 million, or 33.3%, from approximately HK\$2.4 million for the year ended 31 March 2016 to approximately HK\$3.2 million for the year ended 31 March 2017.

DIVIDENDS

Details of the dividends declared and distributed by the Company during the year ended 31 March 2017 are set out in note 12 to the consolidated financial statements.

The Board recommends the payment of a final dividend of HK0.2 cent per Share for the year ended 31 March 2017 to the Shareholders whose names appear on the register of members of the Company on Thursday, 3 August 2017. Subject to the approval of the Shareholders at the annual general meeting of the Company for the year ended 31 March 2017 (the "AGM"), the final dividend will be posted on Friday, 18 August 2017 by ordinary mail to the Shareholders.

As far as the Company is aware, as at the date of this report, there was no arrangement under which any Shareholder has waived or agreed to waive any dividend proposed to be distributed for the year ended 31 March 2017.

CAPITAL STRUCTURE, LIQUIDITY AND FINANCIAL RESOURCES

The capital of the Group only comprises ordinary Shares.

The total equity of the Group as at 31 March 2017 was approximately HK\$82.6 million (2016: approximately HK\$37.8 million). The Group generally financed its operation with internally generated cash flows. The Group had bank balances and cash of approximately HK\$28.5 million as at 31 March 2017 (2016: approximately HK\$30.0 million), with no external borrowing (2016: Nil). As at 31 March 2017, the Group had net current assets of approximately HK\$24.1 million (2016: approximately HK\$28.3 million).

Cash generated from operations for the year ended 31 March 2017 was approximately HK\$16.7 million (2016: approximately HK\$3.8 million). With the healthy bank balances and cash on hand, the Group's liquidity position remained strong and it had sufficient financial resources to fund its future plans and to meet its working capital requirement. As at 31 March 2017, the Group had unused banking facilities of HK\$4.0 million (2016: HK\$4.0 million).

SIGNIFICANT INVESTMENTS HELD BY THE GROUP

During the year ended 31 March 2017, there was no significant investment held by the Group.

FUTURE PLANS FOR MATERIAL INVESTMENTS AND CAPITAL ASSETS

Save as disclosed above and in the prospectus issued by the Company dated 12 December 2014 (the "Prospectus"), the Group does not have other plans for material investments and capital assets.

MATERIAL ACQUISITIONS AND DISPOSALS OF SUBSIDIARIES AND AFFILIATED COMPANIES

The Group did not have any material acquisitions or disposals of subsidiaries and affiliated companies during the year ended 31 March 2017.

MANAGEMENT DISCUSSION AND ANALYSIS

COMMITMENTS

The contractual commitments of the Group were primarily related to the leases of its office premises and the Medicskin Centres. As at 31 March 2017, the Group's operating lease commitments amounted to approximately HK\$11.3 million (2016: approximately HK\$18.7 million).

As at 31 March 2017, the Group had capital commitments in respect of acquisition of property, plant and equipment of approximately HK\$178,000 (2016: HK\$465,000).

CONTINGENT LIABILITIES

As at 31 March 2017, the Group did not have material contingent liabilities.

CHARGES ON THE GROUP'S ASSETS

Details of charges on the Group's assets are set out in note 17 to the consolidated financial statements.

FOREIGN EXCHANGE EXPOSURE

The Group carries out its business in Hong Kong and most of its transactions are denominated in Hong Kong dollars. The Group currently does not have significant foreign currency exposure. The management continually assesses and monitors the foreign exchange exposure and, if necessary, will hedge its foreign exchange exposure by entering forward foreign exchange contracts.

PRINCIPAL RISKS AND UNCERTAINTIES

The Board, as assisted by the audit committee of the Company (the "**Audit Committee**"), oversees the Group's internal control and risk management system, and conducts periodic reviews of such system to ensure good corporate governance practice. The supervision process and outcome of the latest review is set out in more detail in the section headed "Internal Control and Risk Management" in corporate governance report in this report (the "**Corporate Governance Report**"). The following is a discussion of the principal risks and uncertainties facing the Group. The Board meets periodically to discuss these risks, and where appropriate, will monitor the situation closely and adopt any necessary risk mitigation measures.

Business risk

The Group business is dependent on its ability to attract and retained skilled registered medical practitioners and other competent skin care professionals. The Group's ability to provide its services is reliant on the services of these professionals. The ability to attract and retain them is dependent on several factors such as the Group continued reputation, financial remuneration and job satisfaction. In the event that the Group is unable to find suitable and timely replacements should a significant number of the Registered Medical Practitioners resign, our financial position and results, business operations as well as future growth and prospects may be adversely affected. The number of registered medical practitioners with necessary experience and qualifications is limited in the market and the Group are competing for suitable candidates with other medical skin care services providers. We may not be able to attract and retain sufficient suitable registered medical practitioners to enter into or maintain cooperative agreement or employment contract with the Group to keep pace with the growth of the Group.

MANAGEMENT DISCUSSION AND ANALYSIS

Industry risk

The medical skin care industry is sensitive to negative media reports or allegations, which may affect consumer confidence, reputation and market perception of the industry. The industry is also subject to rapidly changing market trends and intense competition amongst different players, including both medical skin care service providers and beauty parlours without medical staff. This may materially and adversely affect the Group's business performance. To maintain competitiveness, our doctors seek to keep abreast of the latest and most suitable treatment products and technology available.

Regulatory and political risk

The Hong Kong government has been reviewing existing laws and regulations which may affect compliance standards of certain procedures, such as those carried out by the Group. However, we are committed to health and safety and most of our treatment services are only performed by doctors.

Our operations are based in Hong Kong and are vulnerable to economic, social and political conditions, such as social unrest or civil disturbance, especially those which may disrupt our clients' and staff's access to our centres and in turn our business performance.

Economy risk

The continued growth in revenue from the Group's operations is highly dependent on the sustainable growth of consumer spending on medical skin care services and products. However, there is no assurance that the local economy can sustain a stable growth in consumer spending. Moreover, if the local economy slows down, it is highly likely that consumer demand and spending on medical skin care services and products may be reduced. Any continued economic slowdown or recession may result in a decrease in consumer spending in relation to medical skin care services and products, and may lead to a material adverse effect upon the Group's business and results of operations.

Reputation risk

The Group's success depends to a significant extent on the recognition of the Group's brand and reputation in the medical skin care services industry as a reliable services provider. Any litigation claims or complaints from the Group's clients in relation to the quality of services or products provided by the Group's Medicskin Centres may adversely affect the reputation and image of the Group, and may in turn, materially and adversely affect the demand for the Group's services.

Severe communicable and uncontrollable disease

As a substantial part of the Group's revenue is derived from clients in Hong Kong which is in close proximity to the PRC, any outbreak of severe communicable disease in Hong Kong or the PRC may have an adverse effect on the economic conditions and consumer environment in Hong Kong and our future growth and overall financial position will be adversely affected.

Financial risk

Credit risk

To minimise credit risk, the Group has monitoring procedures to ensure there is follow-up action to recover overdue debts. The Group also reviews the recoverable amount of each individual debt at the end of each reporting period to ensure that adequate impairment losses are made for irrecoverable amounts. The Board therefore considers that the Group's credit risk is significantly reduced.

MANAGEMENT DISCUSSION AND ANALYSIS

Liquidity risk

The Group monitors and maintains a level of cash and cash equivalents which it deems adequate to finance the Group's operations and mitigate the effects of cash flow fluctuations. As at 31 March 2017 and 2016, the Group had no external borrowing.

Interest risk

The Group is exposed to cash flow interest rate risk in relation to floating rate bank balances. It does not currently have any interest rate hedging policy, but closely monitors its exposure to interest rate risk due to changes in market rates and will consider hedging changes should the need arise.

EMPLOYEES AND REMUNERATION POLICIES

As at 31 March 2017, the Group employed a total of 45 full-time and 3 part-time employees (2016: 49 full-time and 3 part-time employees). The staff costs, including Directors' emoluments, of the Group were approximately HK\$31.1 million for the year ended 31 March 2017 (2016: approximately HK\$32.7 million). Remuneration is determined with reference to factors such as comparable market salaries and the performance, time commitment and responsibilities of each individual. Employees are provided with relevant in-house and/or external trainings from time to time. In addition to a basic salary, year-end bonuses are offered to those staff with outstanding performance to attract and retain eligible employees to contribute to the Group. The Company has adopted a share option scheme (the "**Share Option Scheme**") on 3 December 2014 under which the Company may grant share options to eligible employees for subscribing the Shares.

COMPARISON OF BUSINESS OBJECTIVES WITH ACTUAL BUSINESS PROGRESS

An analysis comparing the business objectives as set out in the Prospectus with the Group's actual business progress for the period from the date of the Listing to 31 March 2017 is set out below:

Business objectives

Actual progress

- | | |
|--|---|
| (i) Expand and strengthen our presence in Hong Kong | <ul style="list-style-type: none">– The Group used approximately HK\$6.4 million for relocation of its Central Medicskin Centre to another prime location within the Central district. The new Central Medicskin Centre was opened in May 2016.– The Group has acquired the Property on 24 March 2017. Upon expiration of the existing lease of the Property in February 2018, the Property will be used as a new skin care centre of the Group. |
| (ii) Enhance quality and variety of our services and products offering | The Group used approximately HK\$4.1 million for enhancement of quality and variety of its services and products offerings in which HK\$3.4 million was used for purchase of new medical devices and HK\$0.7 million was used for development and procurement of new skin care products. |
| (iii) Maintain and enhance our professional expertise | The Group has organised and provided trainings to our doctors and professional staff. |

MANAGEMENT DISCUSSION AND ANALYSIS

USE OF PROCEEDS

The net proceeds from the Placing (as defined in the Prospectus) were approximately HK\$22.9 million, which was based on the placing price of HK\$0.6 per Share and the actual expenses related to the Listing. After the Listing, these proceeds were and will be used for the purposes in accordance with the future plans as set out in the Prospectus.

The net proceeds from the Placing from the date of the Listing to 31 March 2017 were used as follows:

	Planned use of proceeds as shown in the Prospectus from the date of the Listing to 31 March 2017 (adjusted on a pro rata basis based on the actual net proceeds) <i>HK\$'000</i>	Actual use of proceeds from the date of the Listing to 31 March 2017 <i>HK\$'000</i>	Unutilised amount as at 31 March 2017 <i>HK\$'000 (note a)</i>
Expand and strengthen our presence in Hong Kong	11,804	(6,437)	5,367
Enhance quality and variety of our services <i>(note b)</i>	4,072	(4,072)	–
Repayment of debts	4,777	(4,777)	–
Working capital	2,293	(2,293)	–
	<hr/> 22,946	<hr/> (17,579)	<hr/> 5,367

Notes:

- (a) The unused proceeds are deposited in a licensed bank in Hong Kong.
- (b) Actual use of proceeds on expand and strengthen our presence in Hong Kong was lower than the planned use of proceeds because the Group planned to open a new skin care centre at the Property upon expiration of the existing lease of the Property which is expected to end on or before 21 February 2018.

REPORT OF THE DIRECTORS

The Directors submit their report together with the audited consolidated financial statements of the Group for the year ended 31 March 2017.

PRINCIPAL ACTIVITIES AND BUSINESS REVIEW

The Company is an investment holding company. The Group is principally engaged in the provision of medical skin care services. Details of the Group's subsidiaries as at 31 March 2017 are set out in note 29 to the consolidated financial statements.

Details of the business review, including analysis of the Group's performance using financial key performance indicators, principal risks and uncertainties faced by the Group and an indication of likely future developments in the Group's business are set out in the Chairman's Statement and Management Discussion and Analysis on pages 3 to 12.

Environmental policies and performance

The Group is committed to the long term sustainability of the environment and communities in which it engages. The Group strives to minimize its impact on the environment by reducing its use of electricity and water and encouraging recycle of office supplies and other materials. The Group has complied with all relevant laws and regulations regarding environmental protection, health and safety, workplace conditions and employment.

Compliance with the laws and regulations

The Group recognises the importance of compliance with regulatory requirements and the risks of non-compliance with the applicable laws and regulations. During the year ended 31 March 2017 and up to the date of this report, the Group has complied in material respects with the relevant laws and regulations that have a significant impact on the business and operation of the Group. There was no material breach or non-compliance with the applicable laws and regulations by the Group for the year ended 31 March 2017 and up to the date of this report.

Relationship with employees, clients, suppliers and other stakeholders

The Group understands the success of the Group's business depends on the support from its key stakeholders, including employees, clients, suppliers, banks, regulators and Shareholders. During the year ended 31 March 2017, there were no material and significant disputes between the Group and its key stakeholders. The Group will continue to ensure effective communication and maintain good relationship with each of its key stakeholders.

RESULTS AND APPROPRIATIONS

The results of the Group for the year ended 31 March 2017 are set out in the consolidated statement of profit or loss and other comprehensive income on pages 49.

The Board recommends the payment of a final dividend of HK0.2 cent per Share for the year ended 31 March 2017. Subject to the approval of the Shareholders at the AGM, the proposed final dividend will be posted on Friday, 18 August 2017 by ordinary mail to the Shareholders whose names appear on the register of members of the Company on Thursday, 3 August 2017. Based on 480,400,000 Shares in issue as of the date of this report, the total dividend will amount to approximately HK\$1.0 million.

ANNUAL GENERAL MEETING

The AGM will be held on Wednesday, 26 July 2017. A notice convening the meeting will be issued and sent to the Shareholders in due course.

REPORT OF THE DIRECTORS

CLOSURE OF REGISTER OF MEMBERS

For determining the entitlement to attend and vote at the AGM, the register of members of the Company will be closed from Friday, 21 July 2017 to Wednesday, 26 July 2017, both dates inclusive, during which period no transfer of Shares can be registered. In order to be eligible to attend and vote at the AGM, all transfers accompanied by the relevant share certificates must be lodged with the Company's branch share registrar and transfer office in Hong Kong, Tricor Investor Services Limited, at Level 22, Hopewell Centre, 183 Queen's Road East, Hong Kong for registration not later than 4:30 p.m on Thursday, 20 July 2017.

For determining the entitlement to the proposed final dividend, the register of members of the Company will be closed from Tuesday, 1 August 2017 to Thursday, 3 August 2017, both dates inclusive, during which period no transfer of Shares will be registered. In order to qualify for the entitlement to the proposed final dividend, all transfers of Shares, accompanied by the relevant share certificates, must be lodged with the Company's branch share registrar and transfer office in Hong Kong, Tricor Investor Services Limited at the above address for registration not later than 4:30 p.m on Monday, 31 July 2017.

FINANCIAL SUMMARY

A summary of the published results, assets and liabilities of the Group for the last five financial years is set out on page 91. The summary does not form part of the audited consolidated financial statements.

RESERVES

Movements in the reserves of the Group and the Company during the year are set out in the consolidated statement of changes in equity on page 52 and on page 90, respectively.

PROPERTY, PLANT AND EQUIPMENT

Details of the movements during the year in the property, plant and equipment of the Group are set out in note 14 to the consolidated financial statements.

BANK LOANS AND OTHER BORROWINGS

As at 31 March 2017, the Group did not have bank loans or other borrowings.

SHARE CAPITAL

Details of the movements during the year in the share capital of the Company are set out in note 22 to the consolidated financial statements.

FUND RAISING ACTIVITY

On 29 September 2016, a subscription agreement was entered into between the Company and Rich Unicorn, pursuant to which the Company has conditionally agreed to allot and issue, and Rich Unicorn has conditionally agreed to subscribe for, 80,000,000 Subscription Shares at the subscription price of HK\$0.648 per Subscription Share. The Subscription Price represented (i) a discount of 19.00% to the closing price of HK\$0.80 per Share as quoted on the Stock Exchange on 29 September 2016, being the date of the Subscription agreement; and (ii) a discount of approximately 10.99% to the average closing price of HK\$0.728 per Share for the last five trading days immediately prior to the date of the Subscription agreement.

REPORT OF THE DIRECTORS

The Board considered that, the Subscription broadened the Shareholder base of the Company and brought in a renowned investor with strong financial resources and extensive business network, which in turn would bring strategic value to the Group as well as provide synergy to the Group in the development of its business in the medical skin care industry.

The completion of the Subscription took place on 25 October 2016. The gross proceeds from the Subscription were approximately HK\$51.8 million and the net proceeds from the Subscription, after deduction of actual related expenses of approximately HK\$1.6 million were approximately HK\$50.2 million. The Company intended to use the net proceeds from the Subscription for acquisition of premises and initial set-up costs in relation to a new Medicskin Centre to be established in a prime district in Hong Kong in the second quarter in 2017. On 24 March 2017, Golden Dickson acquired the Property at a total consideration of HK\$44.0 million which was financed by the net proceeds from the Subscription. The Property was intended to be used as a new skin care centre upon expiration of the existing lease of the Property which is expected to end on or before 21 February 2018.

For details of the Subscription and the acquisition of the Property, please refer to the announcements of the Company dated 29 September 2016 and 24 January 2017 respectively.

PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES

During the year ended 31 March 2017, neither the Company nor any of its subsidiaries had purchased, sold or redeemed any of the Company's listed securities.

PRE-EMPTIVE RIGHTS

There are no provisions for pre-emptive rights under the articles of association of the Company (the "**Articles of Association**") or the laws of the Cayman Islands that would oblige the Company to offer new Shares on a pro rata basis to existing Shareholders.

DISTRIBUTABLE RESERVES OF THE COMPANY

Pursuant to the Companies Law, Chapter 22 (Law 3 of 1961, as consolidated and revised) of the Cayman Islands, share premium and retained profits of the Company are distributable to the shareholders. As at 31 March 2017, the Company's reserves available for distribution to the Shareholders amounted to approximately HK\$75.1 million.

MAJOR CLIENTS AND SUPPLIERS

For the year ended 31 March 2017, the percentage of revenue derived from our five largest clients in aggregate was less than 2% (2016: 2%).

For the year ended 31 March 2017, our largest supplier accounted for approximately 17.7% (2016: 15.2%) of our total purchases. For the year ended 31 March 2017, our five largest suppliers in aggregate accounted for approximately 67.2% (2016: 61.3%) of our total purchases.

REPORT OF THE DIRECTORS

None of the Directors, their respective close associates or any Shareholders which to the Directors' knowledge own more than 5% of the Company's issued share capital had an interest in any of the Group's five largest suppliers during the year ended 31 March 2017.

DIRECTORS

The Directors during the year and up to the date of this report were as follows:

Executive Directors

Dr. Kong Kwok Leung (*Chairman*)

Mr. Lo Kwok Bun (*Chief Executive Officer*)

Ms. Kong Chung Wai

Ms. Sin Chui Pik Christine (appointed on 1 January 2017)

Independent Non-executive Directors

Mr. Chan Cheong Tat

Mr. Lee Ka Lun

Mr. Leung Siu Cheung

Pursuant to the Articles of Association, Mr. Lo Kwok Bun, Ms. Sin Chui Pik Christine and Mr. Leung Siu Cheung will retire and, being eligible, offer themselves for re-election at the forthcoming AGM.

DIRECTORS' SERVICE CONTRACTS

Each of the executive Directors has entered into a service agreement with the Company for an initial term of three years commencing from the date of the Listing and continuing thereafter until terminated by either party by giving not less than three months' notice in writing to the other.

Each of the independent non-executive Directors has entered into a service agreement with the Company for a term of three years commencing from the date of the Listing, provided that either the Company or the independent non-executive Directors may terminate such appointment at any time by giving at least three months' notice in writing to the other.

Save as aforesaid, none of the Directors proposed for re-election at the forthcoming AGM of the Company has a service contract with the Company or any of its subsidiaries which is not determinable by the Company within one year without payment of compensation (other than statutory compensation).

There are no directors' service contracts that are exempt under Rule 17.91 of the GEM Listing Rules.

DIRECTORS' INTERESTS IN CONTRACTS

Save as disclosed in the section headed "Continuing Connected Transactions" below and in note 27 to the consolidated financial statements and those exempted from the reporting, annual review, announcement and independent Shareholders' approval requirements under the GEM Listing Rules, no contract of significance to the business of the Group to which the Company, its holding companies, its subsidiaries, or its controlling Shareholders was a party subsisted at the end of the year or at any time during the year ended 31 March 2017, and no Directors are or were materially interested either directly or indirectly in any such contract.

REPORT OF THE DIRECTORS

INDEPENDENT NON-EXECUTIVE DIRECTORS

The Company has received, from each of the independent non-executive Directors, an annual confirmation of his independence pursuant to Rule 5.09 under the GEM Listing Rules. The Company considers all of the independent non-executive Directors are independent.

MANAGEMENT CONTRACTS

No contracts concerning the management and administration of the whole or any substantial part of the business of the Group were entered into or existed during the year ended 31 March 2017.

PERMITTED INDEMNITY PROVISION

A permitted indemnity provision for the benefit of the Directors is currently in force and was in force during the year ended 31 March 2017. The Company has arranged for appropriate insurance cover for Directors' and officers' liabilities in respect of legal actions against its Directors and senior management arising out of corporate activities.

EMOLUMENT POLICY

We have established a remuneration committee (the "**Remuneration Committee**") in compliance with the GEM Listing Rules. The primary duties of the Remuneration Committee are to review and make recommendations to the Board on the remuneration policy and other remuneration related matters, including benefits-in-kind and other compensation payable to the Directors and senior management, after consultation with the chairman and/or chief executive officer.

Under the remuneration policy of the Company, the Remuneration Committee will consider factors such as corporate and individual performance, salaries paid by comparable companies, time commitment, responsibilities and employment conditions elsewhere in the Group in assessing the amount of remuneration payable to the Directors and senior management.

NON-COMPETITION UNDERTAKINGS

Pursuant to the deed of non-competition dated 11 December 2014, each of Dr. Kong Kwok Leung ("**Dr. Kong**") and Topline Worldwide Limited ("**Topline**"), a company wholly-owned by Dr. Kong has jointly and severally agreed and undertaken with the Company (for the benefit of itself and each of its subsidiaries), inter alia, that with effect from the date of the deed of non-competition until the earlier of the date on which Dr. Kong and Topline cease to be controlling Shareholders of the Group and the date on which the Shares cease to be listed on the Stock Exchange, he/it will not and will procure that none of his/its associates (other than the Group) will, on its own account or with each other or in conjunction with or on behalf of any person, firm or company, carry on or be engaged in, or be interested in, directly or indirectly, whether as a shareholder (other than being a Director or a Shareholder of the Group or its subsidiaries), Director, employee or otherwise, in any business that competes or may compete, directly or indirectly, with any businesses as may from time to time be carried on by the Group in Hong Kong (other than as a holder of not more than 5% of the issued Shares or stock of any class or debentures of any company listed on any recognised stock exchange).

COMPETING INTERESTS

The Directors are not aware of any business or interest of the Directors nor the controlling Shareholders of the Company nor any of their respective close associates (as defined under the GEM Listing Rules) that competes or may compete, either directly or indirectly, with the business of the Group, or of any other conflicts of interest which any such person has or may have with the Group during the year ended 31 March 2017.

REPORT OF THE DIRECTORS

DISCLOSURE OF INTERESTS

(A) Directors' and Chief Executive' Interests and Short Positions in Shares, Underlying Shares and Debentures

As at 31 March 2017, the interests and short positions of the Directors and chief executive of the Company in the Shares, underlying Shares and debentures of the Company or any of its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance ("SFO")), as recorded in the register maintained by the Company pursuant to Section 352 of the SFO, or as otherwise notified to the Company and the Stock Exchange pursuant to the required standard of dealings by directors of listed issuers as referred to in Rules 5.46 to 5.67 of the GEM Listing Rules were as follows:

Long position

(a) Ordinary Shares of the Company

Name of Director	Capacity/Nature of interest	Number of Shares	Percentage of issued Share capital
Dr. Kong (<i>note</i>)	Interest in a controlled corporation	277,000,040	57.66%

Note: The 277,000,040 Shares are registered in the name of Topline. Under the SFO, Dr. Kong is deemed to be interested in all the Shares registered in the name of Topline.

(b) Options to subscribe for ordinary Shares of the Company

Particulars of the Directors' interests in Share Option Scheme were as follows:

Name of Director	Grant date	Exercise price per Share	Vesting period	Exercise period	Number of share options As at 1.4.2016 and 31.3.2017
Chan Cheong Tat	17.08.2015	0.67	17.08.2015–16.08.2016	17.08.2016–16.08.2017	400,000
Lee Ka Lun	17.08.2015	0.67	17.08.2015–16.08.2016	17.08.2016–16.08.2017	400,000
Leung Siu Cheung	17.08.2015	0.67	17.08.2015–16.08.2016	17.08.2016–16.08.2017	400,000
					1,200,000

Save as disclosed above, as at 31 March 2017, none of the Directors and chief executive of the Company had any interests or short positions in any Shares, underlying Shares or debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) as recorded in the register required to be kept by the Company pursuant to Section 352 of the SFO or as otherwise notified to the Company and the Stock Exchange pursuant to the required standard of dealings by directors of listed issuers as referred to in Rules 5.46 to 5.67 of the GEM Listing Rules.

REPORT OF THE DIRECTORS

(B) Substantial Shareholders' and Other Persons' Interests and Short Positions in Shares and Underlying Shares

As at 31 March 2017, the following persons (other than a Director or chief executive of the Company) had interests or short positions in the Shares and underlying Shares of the Company as recorded in the register required to be kept under section 336 of the SFO:

Long position in the ordinary Shares of the Company

Name	Capacity/Nature of interest	Number of Shares	Percentage of issued Share capital
Topline (note a)	Beneficial owner	277,040,000	57.66%
Rich Unicorn (note b)	Beneficial owner	80,000,000	16.65%
Fullshare (note b)	Interest in a controlled corporation	80,000,000	16.65%
Magnolia Wealth (note b)	Interest in a controlled corporation	80,000,000	16.65%
Mr. Ji (note b)	Interest in a controlled corporation	80,000,000	16.65%

Notes:

- (a) The entire issued share capital of Topline is beneficially owned by Dr. Kong. Therefore, Dr. Kong is deemed to be interested in all the Shares of the Company held by Topline.
- (b) On 29 September 2016, a subscription agreement was entered into between the Company and Rich Unicorn, pursuant to which the Company has conditionally agreed to allot and issue, and Rich Unicorn has conditionally agreed to subscribe for, 80,000,000 Subscription Shares at the subscription price of HK\$0.648 per Subscription Share. The completion of Subscription took place on 25 October 2016. Rich Unicorn is beneficially owned by Fullshare. Fullshare is in turn owned as to 46.58% by Magnolia Wealth International Limited ("**Magnolia Wealth**"), a company incorporated in the British Virgin Islands with limited liability, whose entire issued share capital is beneficially owned by Mr. Ji Changqun ("**Mr. Ji**"). In addition, Mr. Ji holds 4.75% of Fullshare directly as the beneficial owner. Therefore, Fullshare, Magnolia Wealth and Mr. Ji are deemed to be interested in all the Shares held by Rich Unicorn.

Save as disclosed above, as at 31 March 2017, no other interests or short positions in the Shares or underlying Shares of the Company were recorded in the register required to be kept by the Company under Section 336 of the SFO.

REPORT OF THE DIRECTORS

SHARE OPTION SCHEME

The Company adopted the Share Option Scheme on 3 December 2014 to provide incentive and/or to reward eligible persons for their contribution to, and continuing efforts to promote the interest of, the Group. The terms of the Share Option Scheme are in accordance with the provisions of Chapter 23 of the GEM Listing Rules. The following is a summary of the principal terms of the Share Option Scheme:

(a) Purpose of the Share Option Scheme

The purpose of the Share Option Scheme is to provide incentive and/or to reward eligible persons for their contribution to, and continuing efforts to promote the interest of, the Group.

(b) Who may join

Subject to the terms of the Share Option Scheme, the Board shall be entitled to make an offer to any employee (whether full time or part-time employee) of the Company and its subsidiaries; any executive Directors and non-executive Directors (including independent non-executive Directors) of the Company and any of its subsidiaries; and any person or entity acting in their capacities as advisers or consultants or other contractors or business partners of the Group.

(c) Maximum number of Shares

The total number of Shares in respect of which options may be granted under the Share Option Scheme and any other share options schemes of the Company shall not exceed 10% of the total number of Shares in issue immediately following completion of the placing and the capitalisation issue (as defined in note 24), unless the Company seeks the approval of the Shareholders in general meeting for refreshing the 10% limit under the Share Option Scheme.

(d) Maximum entitlement of each eligible person

No option shall be granted to any eligible person if any further grant of options would result in the Shares issued and to be issued upon exercise of all options granted and to be granted to such person (including exercised, cancelled and outstanding options) in the 12-month period up to and including such further grant would exceed 1% of the total number of Shares in issue.

(e) Time of acceptance and exercise of an option

An offer of grant of an option may be accepted by an eligible person within the date as specified in the offer issued by the Company, being a date not later than 21 days after (i) the date on which the offer was issued, or (ii) the date on which the conditions (if any) for the offer are satisfied, provided that such date shall not be more than 10 years after the date of adoption of the Share Option Scheme.

A consideration of HK\$1 is payable for each acceptance of grant of option(s). Such consideration shall generally not be refundable.

Subject to the other provisions of the Share Option Scheme, an option may be exercised in whole or in part by the grantee (or his personal representatives) at any time before the expiry of the period to be determined and notified by the Board to the grantee which in any event shall not be longer than 10 years commencing on the offer date and expiring on the last day of such 10-year period subject to the provisions for early termination as contained in the Share Option Scheme and provided that the Board may determine the minimum period for which the option has to be held or other restrictions before the exercise of the subscription right attaching thereto.

REPORT OF THE DIRECTORS

(f) Subscription price for Shares

The subscription price of a Share in respect of any particular option granted under the Share Option Scheme shall be a price determined by the Board and notified to an eligible person, and shall be at least the highest of:

- (1) the closing price of the Shares as stated in the Stock Exchange's daily quotations sheet on the offer date, which must be a business day;
- (2) the average of the closing price of the Shares as stated in the Stock Exchange's daily quotation sheets for the five business days immediately preceding the offer date; and
- (3) the nominal value of a Share.

(g) Period of the Share Option Scheme

Subject to earlier termination by the Company in general meeting or the Board, the Share Option Scheme shall be valid and effective for a period of 10 years commencing on the date of adoption of the Share Option Scheme, after which period no further option shall be granted. Subject to the above, in all other respects, in particular, in respect of options remaining outstanding on the expiration of the 10-year period referred to in this paragraph, the provisions of the Share Option Scheme shall remain in full force and effect.

As at 31 March 2017, there were an aggregate of 1,600,000 outstanding options to subscribe for 1,600,000 Shares pursuant to the Share Option Scheme.

CHANGE OF COMPLIANCE ADVISER

The Company and Shenwan Hongyuan Capital (H.K.) Limited (formerly known as "Shenyin Wanguo Capital (H.K.) Limited") have mutually agreed to terminate the compliance adviser agreement dated 3 December 2014 with effect from 1 August 2016 due to the consideration of fee levels.

Ample Capital Limited ("**Ample Capital**") has been appointed as the replacement compliance adviser to the Company pursuant to Rule 6A.27 of the GEM Listing Rules with effect from 1 August 2016. For further details, please refer to the announcement of the Company dated 11 July 2016.

INTERESTS OF COMPLIANCE ADVISER

As at 31 March 2017, as notified by the Company's compliance adviser, Ample Capital (the "**Compliance Adviser**"), neither the Compliance Adviser nor its directors, employees or its close associates (as defined under the GEM Listing Rules) had any interests in relation to the Company which is required to be notified to the Company pursuant to Rule 6A.32 of the GEM Listing Rules.

REPORT OF THE DIRECTORS

AUDIT COMMITTEE

The Company had established the Audit Committee on 3 December 2014 with written terms of reference in compliance with the GEM Listing Rules. Details of the role and work performed by the committee are set out in the Corporate Governance Report.

The Audit Committee has reviewed the audited consolidated financial statements of the Group for the year ended 31 March 2017 and is of the view that such results complied with the applicable accounting standards, the GEM Listing Rules and other applicable legal requirements, and that adequate disclosure has been made.

RETIREMENT BENEFIT SCHEMES

Other than operating a Mandatory Provident Fund Scheme under the Mandatory Provident Fund Schemes Ordinance, the Group has not operated any other retirement benefit schemes for its employees. Particulars of the retirement benefit schemes are set out in note 23 to the consolidated financial statements.

RELATED PARTY TRANSACTIONS

Details of related party transactions of the Group during the year ended 31 March 2017 are set out in note 27 to the consolidated financial statements. Such transactions were either (i) fully exempt from the reporting, announcement, annual review and independent Shareholders' approval requirements under Chapter 20 of the GEM Listing Rules, or (ii) continuing connected transactions under the Cooperation Agreement, as set out in the section headed "Continuing Connected Transactions" below.

CONTINUING CONNECTED TRANSACTIONS

Medicskin Laboratories Limited ("**Medicskin**"), a wholly-owned subsidiary indirectly held by the Company, has entered into a cooperation agreement with Dr. Kong and his sole proprietorship for a term of three years commencing from 1 April 2014 ("**Dr. Kong's Cooperation Agreement**"). Under Dr. Kong's Cooperation Agreement, effective from 1 April 2014, Dr. Kong (through his sole proprietorship) shall perform his obligations (including, inter alia, providing medical and treatment services to the clients at the Medicskin Centres) in consideration of the professional fees from Medicskin, and Medicskin shall perform its obligations (including, inter alia, the provision of management and administrative services and granting the sole proprietorship licences to use the name "Medicskin") in consideration of the sole proprietorship paying Medicskin the fees during the term of Dr. Kong's Cooperation Agreement.

The fees charged by Medicskin are equivalent to all the fees received from clients for the services provided by his sole proprietorship at the Medicskin Centres. The professional fees to which Dr. Kong (through his sole proprietorship) is entitled is determined on the basis of a monthly fixed fee of HK\$130,000 as well as a monthly incentive fee. The monthly incentive fee is calculated with reference to the amount of revenue received from clients at the Medicskin Centres generated directly by Dr. Kong and/or his sole proprietorship. When such revenue generated by Dr. Kong and/or his sole proprietorship exceeds a certain threshold, the excess amount, after deducting the cost of associated consumables used in the treatments, is multiplied by a certain percentage to arrive at the monthly incentive fee. Such percentage is commensurate to those typically offered to other doctors under other cooperation agreements. Dr. Kong may also be entitled to a year-end bonus payable at our discretion. Pursuant to the terms of Dr. Kong's Cooperation Agreement, all the fees received from clients for the services provided by Dr. Kong and/or his sole proprietorship are effectively transferred to Medicskin in the form of the fees.

REPORT OF THE DIRECTORS

Details of other material terms under Dr. Kong's Cooperation Agreement are set out in the Prospectus under the heading of "Connected Transactions".

Dr. Kong is a controlling Shareholder and an executive Director and is therefore a connected person of the Company as defined under the GEM Listing Rules. As such, the sole proprietorship set up by Dr. Kong is also a connected person of the Company. Accordingly, the transactions contemplated under Dr. Kong's Cooperation Agreement constitutes continuing connected transactions of the Company under Chapter 20 of the GEM Listing Rules.

The annual caps for the amount of professional fees payable by Medicskin to Dr. Kong (through his sole proprietorship) under Dr. Kong's Cooperation Agreement for the three years ending 31 March 2017 were determined on the basis of the fixed formula stated in Dr. Kong's Cooperation Agreement which comprises a monthly fixed fee of HK\$130,000 and a monthly incentive fee calculated with reference to the amount of revenue generated directly by Dr. Kong and/or his sole proprietorship.

During the year ended 31 March 2017, pursuant to Dr. Kong's Cooperation Agreement, the total fees paid by Dr. Kong's sole proprietorship to Medicskin and the total professional fees paid by Medicskin to Dr. Kong's sole proprietorship approximately amounted to HK\$14,390,000 (2016: HK\$19,298,000) and HK\$4,028,000 (2016: HK\$5,071,000) respectively.

The annual caps in relation to the continuing connected transactions under Dr. Kong's Cooperation Agreement are as follows:

	Year ending 31 March		
	2015	2016	2017
	HK\$'000	HK\$'000	HK\$'000
Amount of fees payable by Dr. Kong (through his sole proprietorship) to Medicskin	22,500	28,000	35,000
Amount of professional fees payable by Medicskin to Dr. Kong (through his sole proprietorship)	6,000	7,500	9,000

As the applicable percentage ratios (other than the profits ratio) as defined under Rule 19.07 of the GEM Listing Rules calculated with reference to the annual caps on an annual basis under Dr. Kong's Cooperation Agreement are more than 5%, the continuing connected transactions contemplated under Dr. Kong's Cooperation Agreement would be subject to the reporting, announcement, annual review, circular and independent Shareholders' approval requirements under the GEM Listing Rules.

Pursuant to Rule 20.103 of the GEM Listing Rules, the Company had applied for, and the Stock Exchange had agreed to grant a waiver to exempt the Company from strict compliance with the announcement, circular and independent Shareholders' approval requirements under the GEM Listing Rules, in respect of the transactions under Dr. Kong's Cooperation Agreement.

REPORT OF THE DIRECTORS

The independent non-executive Directors have reviewed the continuing connected transactions and confirmed that the transactions have been entered into:

- (i) in the ordinary and usual course of business of the Group;
- (ii) on normal commercial terms or, on terms no less favourable to the Group than terms available to or from independent third parties; and
- (iii) in accordance with the relevant agreement governing them on terms that are fair and reasonable and in the interests of the Shareholders as a whole.

Pursuant to the GEM Listing Rules, the Company engaged the Company's external auditor to perform procedures in accordance with Hong Kong Standard on Assurance Engagements 3000 "Assurance Engagements Other Than Audits or Reviews of Historical Financial Information" and with reference to Practice Note 740 "Auditor's Letter on Continuing Connected Transactions under the Hong Kong Listing Rules" issued by the Hong Kong Institute of Certified Public Accountants (the "HKICPA") in respect of these continuing connected transactions of the Group. The auditor has reported its factual findings to the Board that in relation to the continuing connected transactions:

- (i) nothing has come to their attention that causes them to believe that the continuing connected transactions have not been approved by the Board;
- (ii) for transactions involving provision of services by the Group, nothing has come to their attention that causes them to believe that the transactions were not, in all material respects, in accordance with the Group's pricing policies;
- (iii) nothing has come to their attention that causes them to believe that the transactions were not entered into, in all material respects, in accordance with the relevant agreements governing such transactions; and
- (iv) with respect to the aggregate amount of the continuing connected transactions, nothing has come to their attention that causes them to believe that such transactions have exceeded the maximum aggregate annual value disclosed in the Prospectus.

The Company confirms that it has complied with the disclosure requirements, where appropriate, in accordance with Chapter 20 of the GEM Listing Rules.

Medicskin and Dr. Kong have mutually agreed to terminate Dr. Kong's Cooperation Agreement with effect from 1 January 2017. Medicskin and Dr. Kong have entered into an employment agreement with effect from 1 January 2017. Neither Medicskin nor Dr. Kong is required to make any payment to each other under the termination.

The Directors (including the independent non-executive Directors) are of the view that the terms of the employment agreement have been arrived at after arm's length negotiations, entered into in the ordinary and usual course of business of the Company and are on normal commercial terms, fair and reasonable and in the interests of the Group and the Shareholders as a whole.

REPORT OF THE DIRECTORS

EQUITY-LINKED AGREEMENT

Save as disclosed in the Share Option Scheme above, no equity-linked agreements were entered into during the year ended 31 March 2017 or subsisted as at 31 March 2017.

SUFFICIENCY OF PUBLIC FLOAT

As at the date of this report, based on the information that is publicly available to the Company and to the best knowledge of the Directors, the Directors confirm that the Company maintained the amount of public float as required under the GEM Listing Rules.

EVENTS AFTER THE REPORTING PERIOD

There was not significant event occurred after the reporting period.

AUDITOR

Messrs. Deloitte Touche Tohmatsu was appointed by the Board as the auditor of the Company and there has been no change in auditor since the date of the Listing.

Messrs. Deloitte Touche Tohmatsu will retire, and being eligible, offer themselves for re-appointment at the forthcoming AGM. A resolution for their re-appointment as auditor of the Company will be proposed at the forthcoming AGM. The consolidated financial statements for the year ended 31 March 2017 have been audited by Messrs. Deloitte Touche Tohmatsu.

By Order of the Board
Dr. Kong Kwok Leung
Chairman and Executive Director

16 June 2017

CORPORATE GOVERNANCE REPORT

CORPORATE GOVERNANCE PRACTICES

The Board is committed to maintaining a good corporate governance standard, with the chairman being primarily responsible for establishing relevant practices and procedures. The Board believes that a good corporate governance standard will provide a framework for the Group to formulate its business strategies and policies, and manage the associated risks through effective internal control procedures. It will also enhance the transparency of the Group and strengthen accountability to the Shareholders and creditors. Therefore the Board has reviewed and will continue to review and improve the Company's corporate governance practices from time to time.

The Company adopted the Corporate Governance Code (the "CG Code") contained in Appendix 15 to the GEM Listing Rules as its own code of corporate governance and the Board is satisfied that the Company had complied with the CG Code during the year 31 March 2017.

DIRECTORS' SECURITIES TRANSACTIONS

The Company has adopted a code of conduct regarding securities transactions by the Directors, its employees, and the directors and employees of its subsidiaries and holding companies, who may likely possess inside information on the Company or its securities, on terms no less exacting than the required standard of dealings set out in Rules 5.48 to 5.67 of the GEM Listing Rules. The Company had also made specific enquiry of all the Directors and the Company was not aware of any non-compliance with the required standard of dealings regarding securities transactions by the Directors during the year ended 31 March 2017.

BOARD OF DIRECTORS

Board Composition

As at 31 March 2017, the Board comprised of four executive Directors and three independent non-executive Directors. The composition of the Board is as follows:

Executive Directors

Dr. Kong (*Chairman*)

Mr. Lo Kwok Bun (*Chief Executive Officer*)

Ms. Kong Chung Wai

Ms. Sin Chui Pik Christine

Independent Non-executive Directors

Mr. Chan Cheong Tat

Mr. Lee Ka Lun

Mr. Leung Siu Cheung

CORPORATE GOVERNANCE REPORT

Functions, Roles and Responsibilities of the Board

The Board is responsible for leadership and control of the Group and is collectively responsible for promoting the success of the Group by directing and supervising the Group's affairs. The Board focuses on formulating the Group's overall strategies, authorising the development plan and budget; monitoring financial and operating performance; reviewing the effectiveness of the internal control system; supervising and managing management's performance of the Group; and setting the Group's values and standards. The Board delegates the day-to-day management, administration and operation of the Group to the chief executive officer and senior management. The delegated functions are reviewed by the Board periodically to ensure that they accommodate the needs of the Group. The abovementioned personnel should report back and obtain prior approval from the Board before making any significant decisions or entering into any significant commitments on the Company's behalf, and they may not exceed any authority given to them by resolutions of the Board or the Company.

The independent non-executive Directors bring a wide range of business and financial expertise, experience and independent judgement to the Board, on issues of strategic direction, policies, development, performance and risk management. Through active participation in Board meetings, taking the lead in managing issues involving potential conflict of interests and serving on Board committees, they scrutinise the Company's performance in achieving corporate goals and objectives and monitor performance reporting. By doing so, they are able to contribute positively to the Company's strategy and policies through independent, constructive and informed comments at Board and committee meetings.

Each Director has confirmed that he/she can give sufficient time and attention to the Company's affairs, and has regularly provided information on the number and nature of offices held in public companies or organisations and other significant commitments, including the identity of such companies or organisations and an indication of the time involved.

The Company has arranged appropriate insurance cover for Directors' liabilities in respect of legal actions against them for corporate activities.

Board/Board Committee Meetings

The Board regularly meets in person or through other electronic means of communication at least four times a year to, among other matters, review past financial and operating performance and discuss the Group's direction and strategy. An agenda and accompanying papers together with all appropriate information are sent to all Directors at least three days before each Board or committee meeting so as to ensure timely access to relevant information. Appropriate notice of at least 14 days for regular Board meetings and reasonable notice for other Board committee meetings are given to all Directors, who are all given an opportunity to attend and include matters in the agenda for discussion. Senior management is invited to join Board meetings to enhance communication between the Board and management; the Board and each Director also have separate and independent access to senior management whenever necessary. The company secretary takes detailed minutes of the meetings and keeps records of matters discussed and decisions resolved at the meetings, including any concerns raised or dissenting views expressed by Directors, and the voting results of Board meetings fairly reflect Board consensus. Both draft and final versions of the minutes are sent to all Directors for their comments and records respectively, within a reasonable time after each meeting, and such minutes are open for inspection with reasonable advance notice by any Director. Directors are entitled to have access to board papers and related materials, and any queries will be responded to fully.

CORPORATE GOVERNANCE REPORT

Upon reasonable request to the Board, the Directors can seek independent professional advice in performing their duties at the Company's expense, if necessary. According to the current Board's practice, should a potential conflict of interest involving a substantial Shareholder or Director of the Company arise, the matter is discussed in a Board meeting, as opposed to being dealt with by written resolution. Independent non-executive Directors with no conflict of interest should be present at such meetings. When the Board considers any proposal or transaction in which a Director has a conflict of interest, the Director declares his interest and abstains from voting.

Directors' Attendance at Board/Board Committee Meetings

A summary of all Directors' attendance at the Board meeting and Board committee meetings held during the year ended 31 March 2017 is set out in the following table:

Name of Director	Number of meetings attended			Nomination Committee meetings
	Board meetings	Audit Committee meetings	Remuneration Committee meetings	
Dr. Kong	8/8	N/A	3/3	2/2
Mr. Lo Kwok Bun	8/8	N/A	3/3	N/A
Ms. Kong Chung Wai	8/8	N/A	N/A	2/2
Ms. Sin Chui Pik Christine	8/8	6/6	3/3	2/2
Mr. Chan Cheong Tat	7/8	6/6	3/3	2/2
Mr. Lee Ka Lun	7/8	6/6	3/3	2/2
Mr. Leung Siu Cheung	8/8	6/6	3/3	2/2

CORPORATE GOVERNANCE FUNCTIONS

No corporate governance committee of the Company has been established. In compliance with code provision D.3 of the CG Code, the Board as a whole is responsible for performing the corporate governance duties including: (a) to develop and review the Company's policies and practices on corporate governance; (b) to review and monitor the training and continuous professional development of Directors and senior management; (c) to review and monitor the Company's policies and practices on compliance with legal and regulatory requirements; (d) to develop, review and monitor the code of conduct and compliance manual (if any) applicable to employees and Directors; and (e) to review the Company's compliance with the CG Code and disclosure in the Corporate Governance Report.

CHAIRMAN AND CHIEF EXECUTIVE

In accordance with provision A.2.1 of the CG Code, the roles of chairman and chief executive should be separate and should not be performed by the same individual and their respective responsibilities should be clearly defined in writing. Dr. Kong is the chairman of the Board who is primarily responsible for providing leadership to the Board, overseeing the overall operation of the Group and leading and directing the Group's overall business and development strategies. Dr. Kong also chairs the Board and nomination committee (the "Nomination Committee") meetings and briefs the Board members and Nomination Committee members on the issues arising at the respective meetings to ensure that Directors receive adequate information in a timely manner which is accurate, clear, complete and reliable. He encourages all Directors to make full and active contribution to the Board's affairs and takes the lead to ensure that it acts in the Company's best interest. He aims to ensure constructive relations between executive and non-executive Directors. Mr. Lo Kwok Bun is the chief executive officer of the Company who is primarily responsible for day-to-day management and operation; overseeing risk management; corporate communication and marketing; product development; information technology and accounting matters of the Group.

CORPORATE GOVERNANCE REPORT

Code provision A.2.7 of the CG Code requires the chairman of the Board to hold meetings at least annually with the non-executive Directors (including independent non-executive Directors) without the executive Directors present. During the year ended 31 March 2017, four meetings between the chairman of the Board and the non-executive Directors were held. All independent non-executive Directors attended the meetings.

APPOINTMENT AND RE-ELECTION OF DIRECTORS

Each of the executive Directors has entered into a service agreement with the Company for an initial term of three years commencing from the date of the Listing and continuing thereafter until terminated by either party by giving not less than three months' notice in writing to the other.

Each of the independent non-executive Directors has entered into a service agreement with the Company for a term of three years commencing from the date of the Listing, provided that either the Company or the independent non-executive Directors may terminate such appointment at any time by giving at least three months' notice in writing to the other.

By virtue of article 16.2 of the Articles of Association, the Directors shall have power at any time and from time to time to appoint any person to be a Director, either to fill a casual vacancy or as an addition to the existing Directors. In compliance with the code provision A.4.2 of the CG Code, any Director so appointed shall hold office only until the next general meeting of the Company and shall then be eligible for re-election at that meeting. The Board has delegated the power to the Nomination Committee to make recommendations to the Board on the appointment and re-appointment of Directors. The responsibilities of the Nomination Committee are set out in the sub-heading "Nomination Committee" below. Directors to be appointed will have a formal letter of appointment setting out the key terms and conditions of their appointment.

In compliance with the code provision A.4.2 of the CG Code, every Director shall be subject to retirement by rotation at least once every three years. Furthermore, pursuant to article 16.18 of the Articles of Association, at every annual general meeting of the Company one-third of the Directors for the time being shall retire from office by rotation. A retiring Director shall retain office until the close of the meeting at which he/she retires and shall be eligible for re-election thereat.

DIRECTORS' CONTINUOUS PROFESSIONAL DEVELOPMENT

According to the code provision A.6.5 of the CG Code, all Directors shall participate in continuous professional development to develop and refresh their knowledge and skills to ensure their contribution to the Board remains informed and relevant. The Company would arrange and/or introduce suitable training and information for the Directors to ensure they are fully aware of their responsibilities under statute and common law, the GEM Listing Rules and other applicable legal and regulatory requirements. During the year ended 31 March 2017, the Company had arranged a seminar on the GEM Listing Rules, the Hong Kong Companies Ordinance (the "**Companies Ordinance**") and the SFO for the Directors. All Directors attended the seminar.

All Directors, namely Dr. Kong, Mr. Lo Kwok Bun, Ms. Kong Chung Wai, Ms. Sin Chui Pik Christine, Mr. Chan Cheong Tat, Mr. Lee Ka Lun and Mr. Leung Siu Cheung, have confirmed that they had participated in continuous professional development by attending seminars and reading materials during the year ended 31 March 2017, and have provided a record of their training to the Company, in compliance with the code provision A.6.5 of the CG Code.

CORPORATE GOVERNANCE REPORT

BOARD COMMITTEES

The Board has established three committees, namely, the Audit Committee, the Remuneration Committee and the Nomination Committee, to oversee particular aspects of the Company's affairs. All Board committees are established with written terms of reference, which have complied with the CG Code and are available on the Stock Exchange website at www.hkexnews.hk and the Company's website at www.medicsskin.com and are available to Shareholders upon request. The Board committees are provided with sufficient resources to discharge their duties and, upon reasonable request, are able to seek independent professional advice in appropriate circumstances, at the Company's expense. The Board committees will report back to the Board on their decisions or recommendations.

AUDIT COMMITTEE

The Company had established the Audit Committee on 3 December 2014 with written terms of reference in compliance with the GEM Listing Rules. The primary duties of the Audit Committee are to review and supervise the financial reporting process and internal control system of the Company, make recommendations to the Board on the appointment, reappointment and removal of the external auditor, and review the Company's financial information.

The Audit Committee currently consists of three independent non-executive Directors, namely, Mr. Chan Cheong Tat, Mr. Lee Ka Lun and Mr. Leung Siu Cheung. Mr. Chan Cheong Tat is the chairman of the Audit Committee.

During the year ended 31 March 2017, six meetings of the Audit Committee were held to review and discuss the annual/interim/quarterly results and continuing connected transactions of the Group and discuss with the external auditor regarding the audit approach, and the nature and scope of the audit for the year ended 31 March 2017. Two meetings were attended by the Company's external auditor so that the members of the Audit Committee could exchange their views and concerns on the financial reporting process of the Group with the auditors. All members of the Audit Committee attended the meetings.

Details of the attendance of the members of the Audit Committee in the said meeting are set out under the sub-heading "Directors' Attendance at Board/Board Committee Meetings" above.

The Audit Committee has reviewed the consolidated financial statements of the Group for the year ended 31 March 2017 and this report and is of the view that such results complied with the applicable accounting standards, the GEM Listing Rules and other applicable legal requirements, and that adequate disclosure had been made. The Audit Committee has also reviewed the effectiveness of the internal control system of the Group, as detailed in the section headed "Internal Control and Risk Management" below.

REMUNERATION COMMITTEE

The Company had established the Remuneration Committee on 3 December 2014 with written terms of reference in compliance with the GEM Listing Rules.

The primary duties of the Remuneration Committee are to review and make recommendations to the Board on the remuneration policy and other remuneration related matters, including benefits-in-kind and other compensation payable to the Directors and senior management.

CORPORATE GOVERNANCE REPORT

The Remuneration Committee currently consists of two executive Directors and three independent non-executive Directors, namely, Dr. Kong, Mr. Lo Kwok Bun, Mr. Chan Cheong Tat, Mr. Lee Ka Lun and Mr. Leung Siu Cheung. Mr. Leung Siu Cheung is the chairman of the Remuneration Committee.

During the year ended 31 March 2017, three meetings of the Remuneration Committee was held. The meetings of the Remuneration Committee were held to make recommendations to the Board on the Company's policy and structure for remuneration of the Directors and the senior management and on the establishment of a procedure for developing policy on such remuneration; to determine the remuneration packages of all the executive Directors and the senior management; and to make recommendations to the Board on the remuneration of the independent non-executive Directors. All members of the Remuneration Committee attended the meetings.

NOMINATION COMMITTEE

The Company had established the Nomination Committee on 3 December 2014 with written terms of reference in compliance with the GEM Listing Rules. The primary duty of the Nomination Committee is to make recommendations to the Board regarding the structure, size and composition of the Board and candidates to fill vacancies on the Board.

The Nomination Committee currently consists of two executive Directors and three independent non-executive Directors, namely, Dr. Kong, Ms. Kong Chung Wai, Mr. Chan Cheong Tat, Mr. Lee Ka Lun and Mr. Leung Siu Cheung. Dr. Kong is the chairman of the Nomination Committee.

During the year ended 31 March 2017, two meetings of the Nomination Committee was held. The meeting of the Nomination Committee was held to review the structure and composition of the Board, and to review and make recommendations to the Board on adoption of the Board diversity policy. All members of the Nomination Committee attended the meeting.

The Board adopted the Board diversity policy which aims to set out its approach to achieve diversity on the Board. The Company recognises and embraces the benefits of having a diverse Board to enhance the quality of its performance. The Board has in its composition a balance of skills, expertise, qualifications, experience and diversity of perspectives necessary for independent decision making and fulfilling its business needs. The Board will consider a number of aspects when selecting candidates, including but not limited to gender, age, cultural and educational background, professional experience, skills, knowledge and length of service. All Board appointments will ultimately be based on merit and the contribution that the selected candidates will bring to the Board, having due regard for the benefits of diversity on the Board.

ACCOUNTABILITY AND AUDIT

Financial Reporting

The Board is responsible for overseeing the preparation of financial statements on a going concern basis, with supporting assumptions or qualifications as necessary, for each financial period with a view to ensuring that such financial statements give a true and fair view of the state of affairs of the Group and of the results and cash flow for the financial year.

Management of the Company has provided such explanation and information to the Board to enable the Board to make an informed assessment of the financial and other information put before the Board for approval. This includes monthly management updates to the Board, with a balanced, understandable and sufficiently detailed assessment of the Company's performance, position and prospects, enabling the Board and each Director to discharge their duties under the GEM Listing Rules.

CORPORATE GOVERNANCE REPORT

The Group accounts are prepared in accordance with the GEM Listing Rules, the Companies Ordinance, all relevant statutory requirements and applicable accounting standards. The Group has selected appropriate accounting policies and has applied them consistently based on prudent and reasonable judgements and estimates. The Directors endeavor to ensure a balanced, clear and understandable assessment of the Group's position and prospects in the annual reports, interim reports, quarterly reports, price-sensitive announcements and other disclosures required under the GEM Listing Rules and other regulatory requirements.

The Directors acknowledge their responsibility for the preparation of consolidated financial statements of the Group that give a true and fair view in accordance with Hong Kong Financial Reporting Standards issued by the HKICPA and the disclosure requirements of the GEM Listing Rules and the Companies Ordinance, and for such internal control as the Directors determine is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

The responsibility of the Company's auditor, Messrs. Deloitte Touche Tohmatsu, is set out in the section headed "Independent Auditor's Report" on pages 45 to 48 of this report.

Internal Control and Risk Management

The Board is responsible for maintaining a sound and effective internal control system to safeguard the Company's assets and Shareholders' interests. The Group has the Audit Committee to assist the Board by providing independent view of the effectiveness of the financial reporting process and internal control and risk management systems, and overseeing the audit process.

The Board convened meetings periodically to discuss business risk, financial risk, compliance risks and operation and other risks. The Board, through the Audit Committee, has conducted a review of the effectiveness of the internal control system of the Group, covering all material controls such as financial, operational and compliance controls and risk management functions, and considered that the internal control system and procedures of the Group, including the adequacy of resources, qualifications and experience of staff of the accounting and financial reporting function, and their training programs and budget, are adequate and effective and have complied with the provisions of the CG Code during the year.

Subsequent to 31 March 2017, the Company engaged Shinewing Risk Services Limited as the internal auditor of the Group.

AUDITOR'S REMUNERATION

The Audit Committee is responsible for making recommendation to the Board on the appointment, reappointment and removal of the external auditor, and to approve the remuneration and terms of engagement of the external auditor, and any questions of its resignation or dismissal.

Messrs. Deloitte Touche Tohmatsu was appointed by the Board as the auditor of the Company. The remuneration paid or payable to Deloitte Touche Tohmatsu for services rendered for the year ended 31 March 2017 were as follows:

	<i>HK\$'000</i>
Audit services	560
Non-audit services	
– other services (review of preliminary results announcement and review of continuing connected transactions)	220

CORPORATE GOVERNANCE REPORT

COMPANY SECRETARY

Ms. Sin Chui Pik Christine (“**Ms. Sin**”) was appointed by the Board as the company secretary of the Company (the “**Company Secretary**”) on 23 June 2014. The biographical details of Ms. Sin are set out under the section headed “Biographical Details of Directors and Senior Management” in this report.

The primary duties of the Company Secretary include, but are not limited to, the following: (a) to ensure the Board procedures are followed and that the activities of the Board are carried out efficiently and effectively; (b) to assist the chairman to prepare agendas and Board papers for meetings and disseminate such documents to the Directors and Board committees in a timely manner; (c) to timely disseminate announcements and information relating to the Group; and (d) to maintain formal minutes of the Board meetings and other Board committee meetings.

Ms. Sin has confirmed that she had received no less than 15 hours of relevant professional training for the year ended 31 March 2017, in compliance with Rule 5.15 of the GEM Listing Rules.

SHAREHOLDERS’ RIGHTS

The general meetings of the Company provide an opportunity for communication between the Shareholders and the Board. An annual general meeting of the Company shall be held in each year and at the place as may be determined by the Board. Each general meeting, other than an annual general meeting, shall be called an extraordinary general meeting (“**EGM**”).

To ensure compliance with the CG Code, the notice of the meeting, the annual report and the circular containing information on the proposed resolutions will be sent to the Shareholders at least 20 clear business days before the annual general meeting. Voting at the forthcoming AGM will be by way of a poll. An explanation of the detailed procedures of conducting a poll will be provided to the Shareholders at the commencement of the AGM to ensure that the Shareholders are familiar with such procedures.

Poll results will be counted by the Company’s Hong Kong branch share registrar and transfer office, Tricor Investor Services Limited, and will be posted on the websites of the Company and of the Stock Exchange on the day the shareholders’ meeting is held. The general meetings of the Company provide an opportunity for communication between the Shareholders and the Board. The chairman of the Board as well as the chairmen of the Remuneration Committee, the Nomination Committee and the Audit Committee, or in their absence, other members of the respective committees, are available to answer questions at the Shareholders’ meetings. The Company will also arrange for the external auditor of the Company to attend the annual general meetings to answer relevant questions if necessary.

Separate resolutions are proposed at Shareholders’ meetings on each substantial issue, including the election of individual Directors.

SHAREHOLDERS COMMUNICATION POLICY

The Company has established a shareholders communication policy to set out the Company’s procedures in providing the Shareholders and the investment community with ready, equal and timely access to balanced and understandable information about the Company, in order to enable the Shareholders to exercise their rights in an informed manner and to allow the Shareholders and the investment community to engage actively with the Company.

CORPORATE GOVERNANCE REPORT

Rights to convene an EGM

Pursuant to article 12.3 of the Articles of Association, any two or more members holding at the date of the deposit of the requisition not less than one-tenth of the paid-up capital of the Company carrying the right of voting at general meetings of the Company, shall at all times have the right, by written requisition sent to the Company's principal office as set out in the manner below, to require an EGM to be called by the Board for the transaction of any business specified in such requisition.

The written requisition must state the objects of the meeting, be signed by the requisitionist(s), be marked for the attention of the Board or the Company Secretary and be deposited at the Company's principal place of business in Hong Kong at 21st Floor, New World Tower II, 16-18 Queen's Road Central, Hong Kong.

If within 21 days from the date of the deposit of the requisition the Board fails to proceed to convene such meeting to be duly held within a further 21 days, the requisitionist(s) themselves or any of them representing more than one-half of the total voting rights of all of them may convene a meeting in the same manner, as nearly as possible, as that in which meetings may be convened by the Board provided that any meeting so convened shall not be held after the expiration of three months from the date of deposit of the requisition, and all reasonable expenses incurred by the requisitionist(s) as a result of the failure of the Board shall be reimbursed by the Company to the requisitionist(s).

The notice period to be given to Shareholders for general meetings varies as follows:

- (a) At least 14 days' notice in writing if the proposal constitutes an ordinary resolution of the Company;
- (b) At least 21 days' notice in writing if calling for an annual general meeting or the proposal constitutes a special resolution of the Company in EGM.

Right to Put Enquiries to the Board

Shareholders have the right to put enquiries to the Board. All enquiries shall be in writing and sent by post to the principal place of business of the Company in Hong Kong or by e-mail to christine.sin@medicskin.com for the attention of the Company Secretary.

Right to Put Forward Proposals at General Meetings

There are no provisions allowing the Shareholders to propose new resolutions at the general meetings under the Cayman Islands Companies Law, Chapter 22 (Law 3 of 1961, as consolidated and revised). However, the Shareholders may follow the procedure set out in the section headed "Rights to convene an EGM" above for including a resolution at an EGM. The requirements and procedures are set out above.

Right to Propose a Person for Election as a Director

Detailed procedures for a Shareholder to propose a person for election as a Director are available on the Company's website.

INVESTOR RELATIONS

The Company has established a range of communication channels between itself and its Shareholders, investors and other stakeholders. These include the annual general meeting, the annual, interim and quarterly reports, notices, announcements and circulars and the Company's website at www.medicskin.com.

CONSTITUTIONAL DOCUMENTS

For the year ended 31 March 2017, there had been no significant change in the Company's constitutional documents.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

This report covers certain environmental and social responsibility aspects underlying the Group's business operation in Hong Kong during the year ended 31 March 2017 and is prepared with reference to the Environmental Social and Governance Reporting Guide as set out in Appendix 20 of the GEM Listing Rules (the "**ESG Reporting Guide**").

The Company has complied with the "Comply or explain" provisions set out in the ESG Reporting Guide during the year ended 31 March 2017.

For details of the Group's financial performance and corporate governance matters, please refer to other sections in the annual report of the Company of which this ESG Report forms part.

GROUP POLICIES RELATING TO ENVIRONMENTAL PROTECTION

Clinical Waste

Given the medical skin care treatments provided by our Medicskin Centres may produce used or contaminated sharps such as syringes and needles as well as dressings, our Group is subject to Waste Disposal Ordinance (Cap. 354) (the "**WDO**") and the Water Disposal (Clinical Waste) (General) Regulation (Cap. 354O) (the "**WDR**").

The Group exercises the greatest care possible in managing any clinical waste it may produce. The Group has policies and procedures in place for waste treatment in accordance with the WDO and the WDR. To comply with the WDO and the WDR, all clinical waste is securely separated and collected by a licensed clinical waste collector and delivered to a licensed disposal facility. A detailed record of waste production and collection is also maintained in-house.

During the year ended 31 March 2017, approximately 55kg of clinical waste have been generated as a result of the Group's business operations. The Group complied with all applicable laws and regulation in relation to clinical waste in Hong Kong.

Non-Hazardous Waste

Non-hazardous waste from the Group's operation mainly paper waste from office. With a view to minimize the environmental impact brought by these emission and wastes, the Group has adopted the following paper saving practices:

1. Using of recycled papers, and 100% recycling rate of ink and toner cartridges
2. Setting duplex printing as the default mode for most networks printers
3. Reminding employees to practice photocopying wisely
4. Encouraging the employees to use both sides of paper
5. Separating the paper waste from other waste for easier recycling
6. Placing boxes and trays besides photocopiers as containers to collect single-side paper for reuse purpose

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

Resources Consumption

The Group recognizes the importance of efficient use of resources consumption and aims to develop an energy saving cultures. By reducing the amount of energy consumption in its operations can lead to cost savings and reducing carbon footprint. The measures taken by the Group to promote efficient usage are discussed below:

Electricity

The Group has adopted the following practices:

1. The room temperature in Group's premises is monitored and regulated at 25 degree Celsius to maintain a balance between thermal comfort and electricity consumption.
2. Cleaning air-conditioning systems and dust filters regularly.
3. The lighting of our two Medicskin Centres was upgraded from traditional lighting to energy-saving LED lights. As of the end of the reporting period, the percentage of Medicskin Centres using LED lamps accounted for around 90% of the total.
4. Turn off facilities, lights, air-conditioning when not in use.
5. Activate "Sleep" mode in some of office equipment during office hours, including photocopiers and printers.
6. Turn off unnecessary equipment completely including computers.
7. Make conference calls or use other electronic media to reduce travelling for business meetings.

Water

Payment for water usage has been included in the management fee to the landlords. Thus, consumption data of water cannot be obtained. Nevertheless, the Group regularly reminds and encourages its employees to use water efficiently. The Group implements water saving policy by posting reminders in premises to reduce waste on water usage.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

SOCIAL Employment

The Group has Code of Conduct Policy distributed to employees outlining expectations for employee's conduct, employee's right and benefit. We also set up relevant policies and arrangements for employees including but not limited to recruitment and promotion, compensation and dismissal, benefit programs and performance evaluation.

To attract, retain and motivate employees, the Group has devised a competitive compensation and benefits packages. In addition to the basic package, for instance annual leave, paid sick leave, severance payment, mandatory provident fund, employment compensation insurance, the Group also offers additional compensation and benefits such as paid leaves (study leave, personal emergency leave, marriage leave), group life insurance, year-end bonus, free skincare products, education sponsorship, medical treatments and beauty products discount to its employees.

The Group carries out regular performance assessment on a yearly basis, enabling employees to gain an accurate sense of their prospects and of potential future paths. Salaries are reviewed annually for each grade of employees by the management, to ensure that its remuneration packages remain competitive. This enable the Group to retain high quality employees and provide them with strong initiatives for performing well.

Equal Opportunity

The Group provides equal opportunities for employees in respect of recruitment, training and development, job advancement, and compensation and benefits. The employees are not discriminated or deprived of such opportunities on the basis of gender, ethnic background, colour, sexual orientation, age, marital status, family status, retirement, disability, pregnancy or any other discrimination prohibited by applicable laws. The Group appreciates the importance of cultural diversity in the development of the Group, and employs employees in a wide range of ages, genders, and ethnicities.

Working Environment

The Group places a strong emphasis on work-life balance and tries to enhance employees' sense of belonging and morale. As a caring employer, the Group caters to the needs and schedules of its employees, offering flexible work-hour arrangements for employees. Complementing these are social activities such as cinema night, Christmas party, monthly departmental tea meal and birthday celebration for each staff, which can help foster a sense of belonging and loyalty.

Health and Safety

The Group implements internal policies including procedures and guidelines to handling equipment, needle sticks, sharp objects and medical waste. The Group also arranges regular employees training on operation safety, handling of emergency & accidents to enhance safety awareness.

During the year ended 31 March 2017, none of our employees were involved in any material accident in the course of employment and the Group has not been subject to any disciplinary actions with respect to occupation safety.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

Development and Training

The Group provides its employees with clear and viable opportunities for self-development and career advancement within the Group. It supports its employees to develop and enhance their professional knowledge and skills to cope with the evolving market environment and compliance level. By providing the following in-house training programs, its employee's competency can be developed further:

Trainings on service-related knowledge, such as, skincare products available at Medicskin Centres, training courses in relation to skin, treatment theories, functions, operations, safety precautions of medical equipment (provided by suppliers of devices), client handling skills and complaint management skills are provided from time to time. In-house trainings are also provided by research and development department which conducts medical research in relation to new technology in the medical skin care field.

All newly-hired employees attend employment orientation to understand the Group operation, working atmosphere, code of conduct and work safety to ensure all newly-hired employees are properly trained. Employees are also encouraged to take external professional trainings to strengthen their work-related expertise, subject to the management's approval, education sponsorship is available to employees in the form of job-related courses provided by external institutions.

Labour Standard

The Group's recruitment process is strictly adhered to the Group's Human Resources Policies and Procedures. Job applicants must complete an "Employment Application Form" with personnel information for internal record keeping and legal compliance. Review and verification of applicant's identity information is required during the recruitment process, and recruitment of child labour is strictly prohibited. Applicants are also required to provide document proofs of academic qualifications and working experience for verifications, applicant who is suspected to have false academic qualifications and working experience will not be employed. The Group enters employment contract with each of its employee in accordance with relevant laws in Hong Kong.

During the year ended 31 March 2017, the Group was not aware of any non-compliance with laws and regulations that have a significant impact relating to employment and labour practices or occupational health and safety. Nor did the Group identify any incidents relating to hire of child and forced labour.

Supply Chain Management

The quality and safety of skincare products are among the top priorities of the Group. The Group has policies and procedures for selecting suitable pharmaceutical products and medicine, skincare products and treatment consumables, as well as selecting reliable and quality suppliers. The Group has been continuously evaluating the performance of its suppliers. Evaluation of a supplier mainly includes background, qualification (for example, holding necessary license to provide such services), quality control of service, past performance and fulfillment of contract.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

Apart from the above measures, to ensure the supply chain of the Group is operating as accurately and efficiently, purchased medicine and skincare products are registered with traceable suppliers and their distribution are shown clearly in our real time inventory system. Inventory review and inventory count are also carried out regularly in each centre.

The Group has over 10 years' business relationship with our top five suppliers. Given the Group's solid and steady relationships with suppliers, the Group believes that it maintains a good and long-term relationship with selected suppliers by successfully establishing mutual trust and understanding. Generally, the Group has the right to reject goods, to require replacement and the payment of damages from its suppliers if the goods are defective or non-conforming.

During the year ended 31 March 2017, the Group did not encounter any material problem in sourcing pharmaceutical products and medicine, skincare products or treatment consumables based on the needs of Medicskin Centres, did not experience any material delays in receiving supplies from suppliers that would have had material impact on our business, financial condition or results of operations.

Product Responsibility

Pharmaceutical Handling & labelling

The Group has standard procedures for storage of pharmaceutical and skincare products. Labels of pharmaceutical products to customers must show name of customers, date of dispensing, name and address of the doctor, name of medicine, dosage per unit, method and dosage of administration and precaution, where applicable.

Advertisement

During the year ended 31 March 2017, the Group complied with the Undesirable Medical Advertisements Ordinance (Cap. 231) to protect public health without publication of advertisements for medicine, surgical appliance or treatment that may induce the seeking of improper management of certain health conditions.

Health and safety

Quality and safety of the pharmaceutical products are ensured through certifications and qualifications from its suppliers.

All treatment devices used to perform treatments on clients are evaluated and assessed by the Group's doctors, with reference to the doctors' clinical knowledge and experience as well as by certain selection criteria including whether the devices are evidenced-based, i.e whether the use, effectiveness or technology of the devices are approved by national government agencies such as Food and Drug Administration of the US (FDA) or Ministry of Food and Drug Safety of Korea (MFDS) and/or supported by independent medical journals, to ensure that they are reliable and are capable of delivering desired outcomes and results of clients.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

Data Protection and Privacy

The Group has policy in place to provide adequate protection and confidentiality of all corporate data and information. Information collected would only be used for the purpose for which it has been collected and clients would be told about how the data collected would be used in the Group's business. The Group prohibits the provision of client information to a third party without authorisation from the clients. Clients reserve the rights to review and revise their data, and also reserve the rights to opt out from any direct marketing activities. All collected personal data is treated confidentially, kept secure and accessible by designated personnel only. Through internal trainings and confidentiality agreements with employees, the Group emphasizes on confidentiality obligations and the legal consequences for the breaches of obligations.

During the year ended 31 March 2017, we did not encounter any quality issue on our purchases or did not receive any defective products that would have had material impact on our business, financial condition or results of operations.

Anti-corruption

The Group is committed to conducting all businesses without undue influence and has regarded honesty, integrity, and fairness as its core values that must be upheld by all directors and employees at all times. To formalise the commitments, a series of policies and handbooks are in place in the Group and has set out the requirements expected of all directors and employees when dealing with its business. Some of the guiding documents include:

Code of Conduct Policy

- Neither directors nor employees shall obtain or provide benefit to clients, contractors, suppliers or people with business relationship with the Group;
- Employees should avoid any conflict of interest situation, when actual or potential conflict of interest arises, the directors or employees shall make a declaration to the management.
- Accepting voluntary gifts must be declared. All directors and employees are required to strictly follow the Gift and Entertainment Policy and have to undergo the approval process as stipulated in that Policy.

Whistleblowing Policy

- Providing the necessary mechanism for employees who report misconduct within the organisation.

Purchasing and Stock Control Policies

- Preventing and managing possible abuse of power and authority, conflict of interest and bribery.

During the year ended 31 March 2017, the Group was in compliance with the Prevention of Bribery Ordinance (Cap. 201) and there were no legal cases regarding corrupt practices brought against the Group or its directors or employees.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

Community Involvement

The Group is fully aware of the importance of interacting with the wider community in fulfilling corporate social responsibility. In this aspect, the Group would explore the possibility to identify suitable partners and support community and environmental programmes that align with the Group's missions and values.

The Group has been supporting Medecins Sans Frontieres ("**MSF**") and placed MSF's donation boxes in the Group's Medicskin Centres to support MSF's worldwide relief work.

The Group will consider from time to time to donate to charitable organisations when the Group records a net profit and has sufficient cash flow.

BIOGRAPHICAL DETAILS OF DIRECTORS AND SENIOR MANAGEMENT

EXECUTIVE DIRECTORS AND COMPANY SECRETARY

Dr. Kong Kwok Leung (江覺亮), aged 63, is an executive Director and the chairman of the Company as well as the founder of the Group. Dr. Kong is the uncle of Ms. Kong Chung Wai, an executive Director. He is responsible for overseeing the overall operation of the Group and leading and directing the Group's overall business and development strategies. He is also the chairman of the Nomination Committee and a member of the Remuneration Committee. Dr. Kong graduated from the Faculty of Medicine of The University of Hong Kong in November 1978 and obtained a Bachelor of Medicine and Bachelor of Surgery (MBBS (HK)). He subsequently obtained a Diploma in Dermatology from the University of London in September 1995 and a Postgraduate Diploma in Practical Dermatology from Cardiff University in October 2007. He had also obtained the qualifications of Diploma in Child Health from Royal College of Physicians of London in January 1985. Dr. Kong has been in private medical practice for more than three decades and has around 20 years of practising experience in the medical skin care services sector. In 1996, Dr. Kong commenced the practice of providing medical skin care services in Central, Hong Kong. In July 2000, Dr. Kong founded the Group by setting up Medicskin to provide skin treatment services.

Mr. Lo Kwok Bun (盧國斌), aged 64, is an executive Director and the chief executive officer of the Group. Mr. Lo joined the Group in May 2013 and is responsible for the day-to-day management and operations overseeing risk management, corporate communication and marketing, product development, information technology and accounting matters of the Group. He is also a member of the Remuneration Committee. Mr. Lo obtained a Bachelor of Science in Management from the Massachusetts Institute of Technology in Cambridge, Massachusetts, USA in June 1978. Mr. Lo has substantial experience in the technology and financial services sector. He had held senior positions with several multi-national banks including the Vice President of The Citibank Private Bank and the Technology Head of the Asia Pacific Division of Private Banking Group of Citibank Private Bank. Mr. Lo was later employed by the HSBC Group from January 1995 to September 2008. During this period, he acted as (i) the Managing Director and Regional Head of eBusiness & Technology Services at HSBC Private Bank (Suisse) SA; (ii) the Managing Director and Head of Information Technology & Systems at HSBC Republic Bank (Suisse) SA.; and (iii) the Director & Head of Information Technology/Systems in HSBC Investment Bank Asia Limited.

Ms. Kong Chung Wai (江聰慧), aged 39, is an executive Director and the legal and compliance officer of the Group. Ms. Kong is the niece of Dr. Kong, the chairman of the Company and an executive Director. She joined the Group in 2001 and is mainly responsible for overseeing the general compliance matters of the Group. She is also a member of the Nomination Committee. Ms. Kong obtained a Bachelor of Business Administration in Accounting from the Hong Kong University of Science and Technology in November 2000 and a Bachelor of Laws degree from the University of London in August 2010. Ms. Kong has been a fellow member of the Association of Chartered Certified Accountants since 2010 and has accumulated over 16 years of accounting, auditing and compliance experience.

Ms. Sin Chui Pik Christine (冼翠碧), aged 38, is an executive Director, the chief financial officer and the Company Secretary of the Company. She joined the Group in March 2014 and is responsible for overseeing the financial and accounting matters of the Group and engaging in company secretarial functions for the Company. Ms. Sin obtained her bachelor's degree of Business Administration in Accounting from The Hong Kong Baptist University in December 2001. Ms. Sin has been a member of the HKICPA, a member and subsequently fellow of the Association of Chartered Certified Accountants since December 2007, April 2007 and April 2012 respectively. She has accumulated over 15 years of accounting and auditing experience. Before joining the Group, Ms. Sin worked for Deloitte Touche Tohmatsu, an international public accounting and auditing firm from 2001 to 2004 and from 2005 to 2014, where she most recently served as a Manager. She also worked as an Accountant of Jetcrown Industrial (Macao Commercial Offshore) Limited from 2004 to 2005.

BIOGRAPHICAL DETAILS OF DIRECTORS AND SENIOR MANAGEMENT

INDEPENDENT NON-EXECUTIVE DIRECTORS

Mr. Chan Cheong Tat (陳昌達), aged 67, was appointed as an independent non-executive Director on 3 December 2014. He is also the chairman of the Audit Committee and a member of the Remuneration Committee and Nomination Committee. Mr. Chan graduated from Central Queensland University with a master degree in financial management in October 1995 through distance learning. He has also been an associate of The Institute of Chartered Secretaries and Administrators (U.K.) since 1974 and The Hong Kong Institute of Chartered Secretaries since 1994. Mr. Chan is also a fellow member of the HKICPA, the Association of Chartered Certified Accountants and the Australian Society of Certified Practising Accountants for over 26 years. Mr. Chan has over 32 years of work experience in the Hong Kong Inland Revenue Department. He was an Assistant Commissioner and was responsible for tax compliance before he retired in 2005. Mr. Chan has been the sole director of a tax consultancy company, C T Tax Consultants Limited, since August 2006. Further, Mr. Chan has been an independent non-executive director of Guangdong Tannery Limited (stock code: 1058) since March 2006. He was an independent non-executive director of Man Sang International Limited (stock code: 938) from January 2015 to December 2016, Noble Jewelry Holdings Limited (currently known as Zhong Fa Zhan Holdings Limited) (stock code: 475) from October 2006 to December 2011 and Wasion Group Holdings Limited (stock code: 3393) from May 2014 to May 2015.

Mr. Lee Ka Lun (李家麟), aged 62, was appointed as an independent non-executive Director on 3 December 2014. He is also a member of the Audit Committee, Remuneration Committee and Nomination Committee. Mr. Lee obtained a Higher Diploma in Accountancy from the Hong Kong Polytechnic (currently known as the Hong Kong Polytechnic University) in November 1978 and has been an associate of the Association of Certified Accountants since 1980 and a fellow member of the Chartered Association of Certified Accountants since 1985. Mr. Lee has over 25 years of experience in the banking and auditing fields. He joined Lloyds TSB Bank Plc (which was then known as Hill Samuel Bank Limited) in 1982 as an Accountant. He was then promoted to Regional Director — Finance and Operation of Lloyds TSB's operations in Asia in 1987 and had been the Regional Deputy Chief Executive of Lloyds TSB Bank plc from 1991 until 2007. Mr. Lee has also been a responsible officer of Asia Investment Research Limited licensed under the SFO to carry on Type 4 (advising on securities) and Type 9 (asset management) regulated activities since July 2008. He also serves as an independent non-executive director of the following four listed companies in Hong Kong:

Name of company	Stock code	Date of appointment
Yuexiu Property Company Limited	0123	April 2000
Chow Sang Sang Holdings International Limited	0116	September 2004
REXLot Holdings Limited	0555	April 2007
Chong Hing Bank Limited	1111	February 2014
Ever Harvest Group Holdings Limited	1549	June 2016

Mr. Leung Siu Cheung (梁兆祥), aged 65, was appointed as an independent non-executive Director on 3 December 2014. He is also the chairman of the Remuneration Committee and a member of the Audit Committee and Nomination Committee. Mr. Leung completed the Law Society Solicitors Qualifying Examinations in 1982 and obtained a Master of Laws in Chinese and Comparative Law from the City University of Hong Kong in 2004. Mr. Leung is a member of the Law Society of Hong Kong and has been a practising solicitor in Hong Kong since October 1983. Mr. Leung has also been a qualified solicitor in England and Wales since 1990, Australian Capital Territory since 1991 and New South Wales of Australia since 1997. He has been a partner of Lo, Chan & Leung, Solicitors and Notaries since 1986. He has over 33 years of professional experience in the legal field and his major area of practice is banking and finance, civil litigation and conveyancing.

BIOGRAPHICAL DETAILS OF DIRECTORS AND SENIOR MANAGEMENT

SENIOR MANAGEMENT

Ms. Sze Betty Suet Ling (施雪玲), aged 37, is the head of business and product development of the Group. She joined the Group in January 2013 and is mainly responsible for overseeing the business development and execution of the Group's corporate communication and product research and development plans. Ms. Sze is also the Medicskin Centre Manager, mainly responsible for planning and coordinating the day-to-day centre operations, staff supervision and evaluations as well as fiscal management for the Medicskin Centre. Ms. Sze obtained a bachelor's degree of Science with a major in Nutritional Sciences from The University of British Columbia in May 2002 and an International Advanced Diploma in Administrative Management from the Institute of Administrative Management in March 2006. Ms. Sze has over 15 years of experience in the field of product development for skincare brands, retail brand management and skincare business development. Before joining the Group, Ms. Sze was employed as an Executive Trainee of Glycel (Hong Kong) Co. Ltd. in February 2004 and was subsequently promoted to be the Business Development Executive in April 2005. Ms. Sze resigned from Glycel (Hong Kong) Co. Ltd. in April 2007. From June 2007 to December 2012, Ms. Sze worked as Product Manager of Belle Cosmetic Limited.

INDEPENDENT AUDITOR'S REPORT

Deloitte.

德勤

To the Shareholders of Medicskin Holdings Limited

(incorporated in Cayman Islands with limited liability)

OPINION

We have audited the consolidated financial statements of Medicskin Holdings Limited (the “**Company**”) and its subsidiaries (collectively referred to as the “**Group**”) set out on pages 49 to 90, which comprise the consolidated statement of financial position as at 31 March 2017, and the consolidated statement of profit or loss and other comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows for the year then ended, and notes to the consolidated financial statements, including a summary of significant accounting policies.

In our opinion, the consolidated financial statements give a true and fair view of the consolidated financial position of the Group as at 31 March 2017, and of its consolidated financial performance and its consolidated cash flows for the year then ended in accordance with Hong Kong Financial Reporting Standards (“**HKFRSs**”) issued by the Hong Kong Institute of Certified Public Accountants (“**HKICPA**”) and have been properly prepared in compliance with the disclosure requirements of Hong Kong Companies Ordinance.

BASIS FOR OPINION

We conducted our audit in accordance with Hong Kong Standards on Auditing (“**HKSAs**”) issued by the HKICPA. Our responsibilities under those standards are further described in the Auditor’s Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Group in accordance with the HKICPA’s Code of Ethics for Professional Accountants (the “**Code**”), and we have fulfilled our other ethical responsibilities in accordance with the Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

KEY AUDIT MATTER

Key audit matter is that matter that, in our professional judgment, was of most significance in our audit of the consolidated financial statements of the current period. This matter was addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on this matter.

INDEPENDENT AUDITOR'S REPORT

Key audit matter

Recognition of revenue from prepaid treatment packages

We identified the recognition of revenue from prepaid treatment packages as a key audit matter due to significant judgments required by management in the application of revenue recognition policies.

As disclosed in note 4 to the consolidated financial statements, the Group recognises revenue from Treatment Service (as defined in note 3 to the consolidation financial statements) when services are provided. Part of the revenue from Treatment Service is deriving from prepaid treatment packages and these prepaid treatment packages have a valid service period. Prepayments received are initially recorded as deferred revenue in the consolidated statement of financial position, and subsequently recognised as revenue when the services are provided to clients. As represented by the directors of the Company, at their discretion, they may extend the service period and allow clients to enjoy the services under the prepaid treatment packages after the expiry dates as stated on the treatment consent forms. Therefore, the directors of the Company are required to exercise judgment in the application of revenue recognition policies. In such assessment, the directors of the Company consider the general practice and grace period normally adopted by the Group as well as historical customer behaviour and usage pattern of the prepaid treatment packages and the recognition criteria under Hong Kong Accounting Standard 18 "Revenue".

For the year ended 31 March 2017, revenue recognised upon provision of service for prepaid packages for Treatment Service and revenue from expiry of unused packages in respect of Treatment Service amounting to approximately HK\$18,504,000 (2016: HK\$14,937,000) and approximately HK\$784,000 (2016: HK\$565,000) respectively were recognised in the consolidated statement of profit or loss and other comprehensive income.

How our audit addressed the key audit matter

Our procedures in relation to recognition of revenue from prepaid treatment packages included:

- Obtaining an understanding of the Group's process on the recognition of the revenue from prepaid treatment packages;
- Assessing and testing key controls over the recognition of the revenue from prepaid treatment packages;
- Checking the recognition of revenue from the used prepaid treatment packages on a sample basis to the respective source documents;
- Challenging the reasonableness of the basis and assumptions of the recognition of the unused packages as revenue; and
- Checking the contract sum of the package, the valid period for the use of the treatment, the number of sessions being entitled and usage of the sessions upon its expiry on a sample basis to the respective source documents.

INDEPENDENT AUDITOR'S REPORT

OTHER INFORMATION

The directors of the Company are responsible for the other information. The other information comprises the information included in the annual report, but does not include the consolidated financial statements and our auditor's report thereon.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

RESPONSIBILITIES OF DIRECTORS AND THOSE CHARGED WITH GOVERNANCE FOR THE CONSOLIDATED FINANCIAL STATEMENTS

The directors of the Company are responsible for the preparation of the consolidated financial statements that give a true and fair view in accordance with HKFRSs and the disclosure requirements of the Hong Kong Companies Ordinance, and for such internal control as the directors determine is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, the directors are responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Group or to cease operations, or have no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Group's financial reporting process.

AUDITOR'S RESPONSIBILITIES FOR THE AUDIT OF THE CONSOLIDATED FINANCIAL STATEMENTS

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion solely to you, as a body, in accordance with our agreed terms of engagement, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with HKSAAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with HKSAAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

INDEPENDENT AUDITOR'S REPORT

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.
- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

The engagement partner on the audit resulting in the independent auditor's report is Wan Chi Lap.

Deloitte Touche Tohmatsu
Certified Public Accountants
Hong Kong

16 June 2017

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the year ended 31 March 2017

	<i>Notes</i>	2017 HK\$'000	2016 HK\$'000
Revenue	5 & 6	62,062	60,073
Other income, gains and losses	7	110	(566)
Inventories used		(8,269)	(7,697)
Staff costs		(31,100)	(32,727)
Depreciation of property, plant and equipment		(3,064)	(2,015)
Other expenses		(15,371)	(13,391)
<hr/>			
Profit before tax	10	4,368	3,677
Income tax expense	11	(1,200)	(1,323)
<hr/>			
Profit and total comprehensive income for the year attributable to owners of the Company		3,168	2,354
<hr/>			
Earnings per share, basic (HK cent)	13	0.73	0.59
<hr/>			
Earnings per share, diluted (HK cent)	13	0.73	0.59
<hr/>			

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at 31 March 2017

	<i>Notes</i>	2017 <i>HK\$'000</i>	2016 <i>HK\$'000</i>
Non-current assets			
Property, plant and equipment	<i>14</i>	56,037	5,488
Rental deposits		2,421	2,822
Deposits paid for purchase of property, plant and equipment		172	1,305
		58,630	9,615
Current assets			
Inventories	<i>15</i>	3,699	2,958
Trade receivables	<i>16</i>	605	311
Deposits and prepayments		1,269	1,871
Tax recoverable		67	812
Pledged bank deposits	<i>17</i>	8,500	8,500
Bank balances and cash	<i>17</i>	28,496	30,032
		42,636	44,484
Current liabilities			
Trade payables	<i>18</i>	985	508
Accrued liabilities	<i>19</i>	3,346	2,021
Deferred revenue	<i>20</i>	14,167	7,675
Dividend payable	<i>12</i>	–	6,000
		18,498	16,204
Net current assets		24,138	28,280
Total assets less current liabilities		82,768	37,895
Non-current liability			
Deferred tax liability	<i>21</i>	170	127
		170	127
Net assets		82,598	37,768

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at 31 March 2017

	<i>Note</i>	2017 HK\$'000	2016 <i>HK\$'000</i>
Capital and reserves			
Share capital	22	4,804	4,000
Reserves		77,894	33,768
<hr/>			
Equity attributable to owners of the Company		82,598	37,768

The consolidated financial statements on pages 49 to 90 were approved and authorised for issue by the Board of Directors on 16 June 2017 and are signed on its behalf by:

Kong Kwok Leung
DIRECTOR

Lo Kwok Bun
DIRECTOR

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the year ended 31 March 2017

	Attributable to owners of the Company					Total HK\$'000
	Share capital HK\$'000	Share premium HK\$'000	Capital reserve HK\$'000 (note)	Share options reserve HK\$'000	Retained profits HK\$'000	
At 1 April 2015	4,000	31,670	2,579	–	8,934	47,183
Profit and total comprehensive income for the year	–	–	–	–	2,354	2,354
Recognition of equity-settled share-based payments (note 24)	–	–	1,003	228	–	1,231
Dividends recognised as distribution (note 12)	–	–	–	–	(13,000)	(13,000)
Transfer to retained profits	–	–	(3,400)	–	3,400	–
At 31 March 2016	4,000	31,670	182	228	1,688	37,768
Profit and total comprehensive income for the year	–	–	–	–	3,168	3,168
Recognition of equity-settled share-based payments (note 24)	–	–	999	139	–	1,138
Exercise of share options	4	337	–	(73)	–	268
Issue of shares	800	51,040	–	–	–	51,840
Transaction costs attributable to issue of shares	–	(1,584)	–	–	–	(1,584)
Dividends recognised as distribution (note 12)	–	(9,000)	–	–	(1,000)	(10,000)
At 31 March 2017	4,804	72,463	1,181	294	3,856	82,598

Note: The capital reserve represents equity-settled share-based payments in respect to the Group's Share Reward as detailed in note 24.

CONSOLIDATED STATEMENT OF CASH FLOWS

For the year ended 31 March 2017

	2017 <i>HK\$'000</i>	2016 <i>HK\$'000</i>
OPERATING ACTIVITIES		
Profit before tax	4,368	3,677
Adjustments for:		
Allowance for bad and doubtful debts	7	15
Interest income on bank deposits	(81)	(225)
Share-based payment expenses	1,138	1,231
Depreciation of property, plant and equipment	3,064	2,015
Allowance for inventories	29	83
Loss on write-off of property, plant and equipment	15	33
Gain on disposal of property, plant and equipment	(23)	–
Operating cash flows before movements in working capital	8,517	6,829
Increase in inventories	(770)	(597)
Increase in trade receivables	(301)	(13)
Decrease (increase) in deposits and prepayments	1,003	(1,411)
Increase in trade payables	477	90
Increase (decrease) in accrued liabilities	1,325	(1,369)
Increase in deferred revenue	6,492	280
Cash generated from operations	16,743	3,809
Net income tax paid	(412)	(1,968)
NET CASH FROM OPERATING ACTIVITIES	16,331	1,841
INVESTING ACTIVITIES		
Interest received	81	225
Increase in pledged bank deposits	–	(8,500)
Proceeds from disposal of property, plant and equipment	31	–
Purchase of property, plant and equipment	(52,331)	(3,252)
Deposits paid for purchase of property, plant and equipment	(172)	(1,305)
NET CASH USED IN INVESTING ACTIVITIES	(52,391)	(12,832)

CONSOLIDATED STATEMENT OF CASH FLOWS

For the year ended 31 March 2017

	2017 <i>HK\$'000</i>	2016 <i>HK\$'000</i>
FINANCING ACTIVITIES		
Dividends paid	(16,000)	(7,000)
Proceeds from exercise of share options	268	–
Proceeds from issue of shares	51,840	–
Transaction costs attributable to issue of shares	(1,584)	–
	<hr/>	<hr/>
NET CASH FROM (USED IN) FINANCING ACTIVITIES	34,524	(7,000)
	<hr/>	<hr/>
NET DECREASE IN CASH AND CASH EQUIVALENTS	(1,536)	(17,991)
	<hr/>	<hr/>
CASH AND CASH EQUIVALENTS AT BEGINNING OF THE YEAR	30,032	48,023
	<hr/>	<hr/>
CASH AND CASH EQUIVALENTS AT END OF THE YEAR, REPRESENTED BY		
Bank balances and cash	28,496	30,032
	<hr/>	<hr/>

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 March 2017

1. GENERAL

The Company was incorporated and registered as an exempted company with limited liability in the Cayman Islands under the Companies Law, Chapter 22 (Law 3 of 1961, as consolidated and revised) of the Cayman Islands on 20 June 2014. The shares of the Company have been listed on the Growth Enterprise Market (“**GEM**”) of the Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) since 18 December 2014. Its immediate and ultimate holding company is Topline Worldwide Limited (“**Topline**”), a company incorporated in British Virgin Islands (“**BVI**”) with limited liability. Its ultimate controlling party is Dr. Kong Kwok Leung (“**Dr. Kong**”), who is also the chairman and executive director of the Company. The addresses of the registered office and principal place of business of the Company are disclosed in the corporation information section of the annual report.

The Company is an investment holding company. The Group is principally engaged in the provision of medical skin care services in Hong Kong.

The functional currency of the Company is Hong Kong dollars, which is the same as the presentation currency of the consolidated financial statements.

2. APPLICATION OF NEW AND AMENDMENTS TO HONG KONG FINANCIAL REPORTING STANDARDS (“**HKFRSs**”)

The Group has applied the following amendments to HKFRSs issued by the Hong Kong Institute of Certified Public Accountants (“**HKICPA**”) for the first time in the current year:

Amendments to HKFRS 11	Accounting for acquisitions of interests in joint operations
Amendments to HKAS 1	Disclosure initiative
Amendments to HKAS 16 and HKAS 38	Clarification of acceptable methods of depreciation and amortisation
Amendments to HKAS 16 and HKAS 41	Agriculture: Bearer plants
Amendments to HKFRS 10, HKFRS 12 and HKAS 28	Investment entities: Applying the consolidation exception
Amendments to HKFRSs	Annual improvements to HKFRSs 2012 – 2014 cycle

Except as described below, the application of the amendments to HKFRSs in the current year has had no material impact on the Group’s financial performance and positions for the current and prior years and/or on the disclosures set out in these consolidated financial statements.

Amendments to HKAS 1 Disclosure Initiative

The Group has applied the amendments to HKAS 1 Disclosure Initiative for the first time in the current year. The amendments to HKAS 1 clarify that an entity need not provide a specific disclosure required by an HKFRS if the information resulting from that disclosure is not material, and give guidance on the bases of aggregating and disaggregating information. However, the amendments reiterate that an entity should consider providing additional disclosures when compliance with the specific requirements in HKFRS is insufficient to enable users of financial statements to understand the impact of particular transactions, events and conditions on the entity’s financial position and financial performance.

As regards the structure of the financial statements, the amendments provide examples of systematic ordering or grouping of the notes.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 March 2017

2. APPLICATION OF NEW AND AMENDMENTS TO HONG KONG FINANCIAL REPORTING STANDARDS (“HKFRSs”) (Continued)

The grouping and ordering of certain notes have been revised to give prominence to the areas of the Group’s activities that management considers to be most relevant to an understanding of the Group’s financial performance and financial position. Specifically, information to capital risk management and financial instruments was reordered to notes 27 and 28. Other than the above presentation and disclosure changes, the application of the amendments to HKAS 1 has not resulted in any impact on the financial performance or financial position of the Group in these consolidated financial statements.

New and amendments to HKFRSs in issue but not yet effective

The Group has not early applied the following new and amendments to HKFRSs that have been issued but are not yet effective:

HKFRS 9	Financial instrument ¹
HKFRS 15	Revenue from contracts with customers and the related amendments ¹
HKFRS 16	Leases ²
HK(IFRIC) - Int 22	Foreign Currency Transactions and Advance Consideration ¹
Amendments to HKFRS 2	Classification and measurement of share-based payment transactions ¹
Amendments to HKFRS 4	Applying HKFRS 9 Financial instruments with HKFRS 4 Insurance contracts ¹
Amendments to HKFRS 10 and HKAS 28	Sale or contribution of assets between an investor and its associate or joint venture ³
Amendments to HKAS 7	Disclosure initiative ⁴
Amendments to HKAS 12	Recognition of deferred tax assets for unrealised losses ⁴
Amendments to HKFRSs	Annual improvements to HKFRSs 2014 – 2016 cycle ⁵

¹ Effective for annual periods beginning on or after 1 January 2018.

² Effective for annual periods beginning on or after 1 January 2019.

³ Effective for annual periods beginning on or after a date to be determined.

⁴ Effective for annual periods beginning on or after 1 January 2017.

⁵ Effective for annual periods beginning on or after 1 January 2017 or 1 January 2018, as appropriate.

HKFRS 15 Revenue from Contracts with Customers

HKFRS 15 was issued which establishes a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. HKFRS 15 will supersede the current revenue recognition guidance including HKAS 18 “Revenue”, HKAS 11 “Construction contracts” and the related Interpretations when it becomes effective.

The core principle of HKFRS 15 is that an entity should recognise revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Specifically, the Standard introduces a 5-step approach to revenue recognition:

- Step 1: Identify the contract(s) with a customer
- Step 2: Identify the performance obligations in the contract
- Step 3: Determine the transaction price
- Step 4: Allocate the transaction price to the performance obligations in the contract
- Step 5: Recognise revenue when (or as) the entity satisfies a performance obligation

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 March 2017

2. APPLICATION OF NEW AND AMENDMENTS TO HONG KONG FINANCIAL REPORTING STANDARDS (“HKFRSs”) *(Continued)*

HKFRS 15 Revenue from Contracts with Customers *(Continued)*

Under HKFRS 15, an entity recognises revenue when (or as) a performance obligation is satisfied, i.e. when ‘control’ of the goods or services underlying the particular performance obligation is transferred to the customer. Far more prescriptive guidance has been added in HKFRS 15 to deal with specific scenarios. Furthermore, extensive disclosures are required by HKFRS 15. In 2016, the HKICPA issued clarifications to HKFRS 15 in relation to the identification of performance obligations, principal versus agent considerations, as well as licensing application guidance.

The directors of the Company (“**Directors**”) anticipate that the application of HKFRS 15 in the future may result in more disclosures, however, the Directors do not anticipate that the application of HKFRS 15 will have a material impact on the timing and amounts of revenue recognised in the respective reporting periods.

HKFRS 16 Leases

HKFRS 16 introduces a comprehensive model for the identification of lease arrangements and accounting treatments for both lessors and lessees. HKFRS 16 will supersede HKAS 17 Leases and the related interpretations when it becomes effective.

HKFRS 16 distinguishes lease and service contracts on the basis of whether an identified asset is controlled by a customer. Distinctions of operating leases and finance leases are removed for lessee accounting, and is replaced by a model where a right-of-use asset and a corresponding liability have to be recognised for all leases by lessees, except for short-term leases and leases of low value assets.

The right-of-use asset is initially measured at cost and subsequently measured at cost (subject to certain exceptions) less accumulated depreciation and impairment losses, adjusted for any remeasurement of the lease liability. The lease liability is initially measured at the present value of the lease payments that are not paid at that date. Subsequently, the lease liability is adjusted for interest and lease payments, as well as the impact of lease modifications, amongst others. For the classification of cash flows, the Group currently presents operating lease payments as operating cash flows. Under the HKFRS 16, lease payments in relation to lease liability will be allocated into a principal and an interest portion which will be presented as financing cash flows.

In contrast to lessee accounting, HKFRS 16 substantially carries forward the lessor accounting requirements in HKAS 17, and continues to require a lessor to classify a lease either as an operating lease or a finance lease.

Furthermore, extensive disclosures are required by HKFRS 16.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 March 2017

2. APPLICATION OF NEW AND AMENDMENTS TO HONG KONG FINANCIAL REPORTING STANDARDS (“HKFRSs”) (Continued)

HKFRS 16 Leases (Continued)

As at 31 March 2017, the Group has non-cancellable operating lease commitments of approximately HK\$11,257,000 as disclosed in note 25. A preliminary assessment indicates that these arrangements will meet the definition of a lease under HKFRS 16, and hence the Group will recognise a right-of-use asset and a corresponding liability in respect of all these leases unless they qualify for low value or short-term leases upon the application of HKFRS 16. In addition, the application of new requirements may result changes in measurement, presentation and disclosure as indicated above. However, it is not practicable to provide a reasonable estimate of the financial effect until the Directors complete a detailed review.

The Directors anticipate that the application of the other new and amendments to HKFRSs will have no material impact on the consolidated financial statements of the Group.

3. SIGNIFICANT ACCOUNTING POLICIES

The consolidated financial statements have been prepared in accordance with HKFRSs issued by HKICPA. In addition, the consolidated financial statements include applicable disclosures required by the Rules Governing the Listing of Securities on the GEM of the Stock Exchange (the “**GEM Listing Rules**”) and by the Hong Kong Companies Ordinance.

The consolidated financial statements have been prepared on the historical basis at the end of each reporting period, as explained in the accounting policies set out below.

Historical cost is generally based on the fair value of the consideration given in exchange for goods and services.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, regardless of whether that price is directly observable or estimated using another valuation technique. Fair value for measurement and/or disclosure purposes in the consolidated financial statements is determined on such a basis, except for share-based payment transactions that are within the scope of HKFRS 2, leasing transactions that are within the scope of HKAS 17, and measurements that have some similarities to fair value but are not fair value, such as net realisable value in HKAS 2 or value in use in HKAS 36.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 March 2017

3. SIGNIFICANT ACCOUNTING POLICIES *(Continued)*

The principal accounting policies adopted are set out below.

Basis of consolidation

The consolidated financial statements incorporate the financial statements of the Company and entities controlled by the Company and its subsidiaries. Control is achieved when the Company:

- has power over the investee;
- is exposed, or has rights, to variable returns from its involvement with the investee; and
- has the ability to use its power to affect its returns.

The Company reassesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control listed above.

Consolidation of a subsidiary begins when the Group obtains control over the subsidiary and ceases when the Group loses control of the subsidiary. Specifically, income and expenses of a subsidiary acquired or disposed of during the year are included in the consolidated statement of profit or loss and other comprehensive income from the date the Group gains control until the date when the Group ceases to control the subsidiary.

When necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies in line with the Group's accounting policies.

All intra-group assets, liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full on consolidation.

Revenue recognition

Revenue is measured at the fair value of the consideration received or receivable and represents amounts received and receivable for goods sold and services provided in the normal course of business, net of discounts and refund.

Revenue is recognised when the amount of revenue can be reliably measured; when it is probably that future economic benefits will flow to the Group and when specific criteria have been met for each of the Group's activities, as described below.

Revenue from provision of consultation services ("**Consultation Service**") are recognised when services are provided.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 March 2017

3. SIGNIFICANT ACCOUNTING POLICIES *(Continued)*

Revenue recognition *(Continued)*

Revenue from provision of medical skin care treatments ("**Treatment Service**") are recognised when services are provided. Prepayments received are initially recorded as deferred revenue in the consolidated statement of financial position, and subsequently recognised as revenue when the services are provided to clients.

Revenue from prescription and dispensing of medication and/or skincare products including sale of skincare products ("**Prescription and Dispensing Service**") are recognised when delivered and titles have passed, at which time all the following conditions are satisfied:

- the Group has transferred to the buyer the significant risks and rewards of ownership of the medication and skincare products;
- the Group retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the medication and skincare products sold;
- the amount of revenue can be measured reliably;
- it is probable that the economic benefits associated with the transaction will flow to the Group; and
- the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Interest income from a financial asset is recognised when it is probable that the economic benefits will flow to the Group and the amount of income can be measured reliably. Interest income is accrued on a time basis, by reference to the principal outstanding and at the effective interest rate applicable, which is the rate that exactly discounts the estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount on initial recognition.

Property, plant and equipment

Property, plant and equipment including buildings and leasehold land (classified as finance leases) held for use in the production or supply of goods or services, or for administrative purposes, are stated in the consolidated statement of financial position at cost less subsequent accumulated depreciation and subsequent accumulated impairment losses, if any.

Depreciation is recognised so as to write off the cost of assets less their residual values over their estimated useful lives, using the straight-line method. The estimated useful lives, residual values and depreciation method are reviewed at the end of each reporting period, with the effect of any changes in estimate accounted for on a prospective basis.

Assets held under finance leases are depreciated over their expected useful lives on the same basis as owned assets. However, when there is no reasonable certainty that ownership will be obtained by the end of the lease term, assets are depreciated over the shorter of the lease term and their useful lives.

An item of property, plant and equipment is derecognised upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. Any gain or loss arising on the disposal or retirement of an item of property, plant and equipment is determined as the difference between the sales proceeds and the carrying amount of the asset and is recognised in profit or loss.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 March 2017

3. SIGNIFICANT ACCOUNTING POLICIES *(Continued)*

Impairment of tangible assets

At the end of the reporting period, the Group reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss, if any.

Recoverable amount is the higher of fair value less costs of disposal and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

If the recoverable amount of an asset is estimated to be less than its carrying amount, the carrying amount of the asset is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss.

Where an impairment loss subsequently reverses, the carrying amount of the asset is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset in prior years. A reversal of an impairment loss is recognised immediately in profit or loss.

Leasing

Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessee. All other leases are classified as operating leases.

The Group as lessor

Rental income from operating leases is recognised on a straight-line basis over the term of the relevant lease. Initial direct costs incurred in negotiating and arranging an operating lease are added to the carrying amount of the leased asset and recognised on a straight-line basis over the lease term.

The Group as lessee

Operating lease payments are recognised as an expense on a straight-line basis over the lease term.

Leasehold land and building

When a lease includes both land and building elements, the Group assesses the classification of each element as a finance or an operating lease separately based on the assessment as to whether substantially all the risks and rewards incidental to ownership of each element have been transferred to the Group, unless it is clear that both elements are operating leases in which case the entire lease is classified as an operating lease. Specifically, the minimum lease payments (including any lump-sum upfront payments) are allocated between the land and the building elements in proportion to the relative fair values of the leasehold interests in the land element and building element of the lease at the inception of the lease.

To the extent the allocation of the lease payments can be made reliably, interest in leasehold land that is accounted for as an operating lease is presented as "prepaid lease payments" in the consolidated statement of financial position and is amortised over the lease term on a straight-line basis. When the lease payments cannot be allocated reliably between the land and building elements, the entire lease is generally classified as a finance lease.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 March 2017

3. SIGNIFICANT ACCOUNTING POLICIES *(Continued)*

Foreign currencies

In preparing the financial statements of each individual group entity, transactions in currencies other than the functional currency of that entity (foreign currencies) are recognised at the rates of exchanges prevailing on the dates of the transactions. At the end of the reporting period, monetary items denominated in foreign currencies are retranslated at the rates prevailing at that date. Non-monetary items that are measured in terms of historical cost in a foreign currency are not retranslated.

Exchange differences arising on the settlement of monetary items, and on the retranslation of monetary items, are recognised in profit or loss in the period in which they arise.

Retirement benefits costs

Payments to Mandatory Provident Fund Scheme (the “**MPF Scheme**”) are recognised as an expense when employees have rendered services entitling them to the contributions.

Share-based payment arrangements

Equity-settled share-based payment transactions

Share options issued to employees and other eligible persons are measured at the fair value of the share options at the grant date. The fair value determined at the grant date of the equity-settled share-based payments is expensed on a straight-line basis over the vesting period, with a corresponding increase in equity. When the share options are forfeited after the vesting date or are still not exercised at the expiry date, the amount previously recognised in the share options reserve will be transferred to retained profits.

For the Share Reward (as defined in note 24) granted to a medical practitioner of the Group by the shareholder (i.e. Dr. Kong) for services rendered to the Group, the fair value of services received is determined by reference to the fair value of the Share Reward at the grant date. The fair value of services received is expensed on a straight-line basis over the vesting period, with a corresponding increase in capital reserve as deemed contribution from the shareholder.

The Group shall recognise, as a minimum, the services received measured at the grant date fair value of the Share Reward granted, unless the Share Reward does not vest because of failure to satisfy a vesting condition (other than a market condition) that was specified at the grant date. In addition, an expense is recognised for the effect of modifications to the terms and conditions on which the Share Reward was granted, if any, that increases the total fair value of the Share Reward or are otherwise beneficial to the employee as measured at the date of the modification.

Borrowing costs

Borrowing costs directly attributable to the acquisition, construction or production of qualifying assets, which are assets that necessarily take a substantial period of time to get ready for their intended use or sale, are added to the cost of those assets until such time as the assets are substantially ready for their intended use or sale.

Investment income earned on the temporary investment of specific borrowings pending their expenditure on qualifying assets is deducted from the borrowing costs eligible for capitalisation.

All other borrowing costs are recognised in profit or loss in the period in which they are incurred.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 March 2017

3. SIGNIFICANT ACCOUNTING POLICIES *(Continued)*

Taxation

Income tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from 'profit before tax' as reported in the consolidated statement of profit or loss and other comprehensive income because of items of income or expense that are taxable or deductible in other year and items that are never taxable or deductible. The Group's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.

Deferred tax

Deferred tax is recognised on temporary differences between the carrying amounts of assets and liabilities in the consolidated financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable temporary differences. Deferred tax assets are generally recognised for all deductible temporary difference to the extent that it is probable that taxable profits will be available against which those deductible temporary differences can be utilised. Such deferred assets and liabilities are not recognised if the temporary difference arises from the initial recognition of assets and liabilities in a transaction that affects neither the taxable profit nor the accounting profit.

The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset is realised, based on tax rate (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.

The measurement of deferred tax liabilities and assets reflects the tax consequences that would follow from the manner in which the Group expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.

Current and deferred tax are recognised in profit or loss.

Inventories

Inventories are stated at the lower of cost and net realisable value. Cost of inventories are determined on a weighted average method. Net realisable value represents the estimated selling price for inventories less all estimated costs of completion and costs necessary to make the sale.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 March 2017

3. SIGNIFICANT ACCOUNTING POLICIES *(Continued)*

Financial instruments

Financial assets and financial liabilities are recognised when a group entity becomes a party to the contractual provisions of the instrument.

Financial assets and financial liabilities are initially measured at fair value. Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities are added to or deducted from the fair value of the financial assets or financial liabilities, as appropriate, on initial recognition.

Financial assets

The Group's financial assets are classified as loans and receivables. The classification depends on the nature and purpose of the financial assets and is determined at the time of initial recognition.

Effective interest method

The effective interest method is a method of calculating the amortised cost of a debt instrument and of allocating interest income over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash receipts (including all fees and points paid or received that form an integral part of the effective interest rate, transaction costs and other premiums or discounts) through the expected life of the debt instrument, or, where appropriate, a shorter period, to the net carrying amount on initial recognition.

Interest income is recognised on an effective interest basis for debt instruments.

Loans and receivables

Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. Subsequent to initial recognition, loans and receivables (including trade receivables, deposits, pledged bank deposits and bank balances and cash) are measured at amortised cost using the effective interest method, less any impairment (see accounting policy on impairment of loans and receivables below).

Interest income is recognised by applying the effective interest rate, except for short-term receivables where the recognition of interest would be immaterial.

Impairment of loans and receivables

Loans and receivables are assessed for indicators of impairment at the end of each reporting period. Loans and receivables are considered to be impaired when there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the loans and receivables, the estimated future cash flows of the loans and receivables have been affected.

For loans and receivables, objective evidence of impairment could include:

- significant financial difficulty of the issuer or counterparty; or
- breach of contract, such as a default or delinquency in interest and principal payments; or
- it becoming probable that the borrower will enter bankruptcy or financial re-organisation.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 March 2017

3. SIGNIFICANT ACCOUNTING POLICIES *(Continued)*

Financial instruments *(Continued)*

Financial assets *(Continued)*

Impairment of loans and receivables (Continued)

For trade receivables that are assessed not to be impaired individually are, in addition, assessed for impairment on a collective basis. Objective evidence of impairment for a portfolio of receivables could include the Group's past experience of collecting payments, an increase in the number of delayed payments in the portfolio past the average credit period and observable changes in national or local economic conditions that correlate with default on receivables.

For financial assets carried at amortised cost, the amount of the impairment loss recognised is the difference between the asset's carrying amount and the present value of the estimated future cash flows discounted at the financial asset's original effective interest rate.

The carrying amount of loans and receivables is reduced by the impairment loss directly with the exception of trade receivables, where the carrying amount is reduced through the use of an allowance account. Changes in the carrying amount of the allowance account are recognised in profit or loss. When a trade receivable is considered uncollectible, it is written off against the allowance account. Subsequent recoveries of amounts previously written off are credited to profit or loss.

For financial assets measured at amortised cost, if, in a subsequent period, the amount of impairment loss decreases and the decrease can be related objectively to an event occurring after the impairment was recognised, the previously recognised impairment loss is reversed through profit or loss to the extent that the carrying amount of the asset at the date the impairment is reversed does not exceed what the amortised cost would have been had the impairment not been recognised.

Financial liabilities and equity instruments

Debt and equity instruments issued by a group entity are classified as either financial liabilities or as equity in accordance with the substance of the contractual arrangements and the definitions of a financial liability and an equity instrument.

Equity instruments

An equity instrument is any contract that evidences a residual interest in the assets of an entity after deducting all of its liabilities. Equity instruments issued by the group entities are recognised at the proceeds received, net of direct issue costs.

Effective interest method

The effective interest method is a method of calculating the amortised cost of a financial liability and of allocating interest expense over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash payments (including all fees and points paid or received that form an integral part of the effective interest rate, transaction costs and other premiums or discounts) through the expected life of the financial liability, or, where appropriate, a shorter period, to the net carrying amount on initial recognition.

Interest expense is recognised on an effective interest basis.

Financial liabilities

Financial liabilities (including trade payables, accrued liabilities and dividend payable) are subsequently measured at amortised cost using the effective interest method.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 March 2017

3. SIGNIFICANT ACCOUNTING POLICIES *(Continued)*

Derecognition

The Group derecognises a financial asset only when the contractual rights to the cash flows from the asset expire, or when it transfers the financial asset and substantially all the risks and rewards of ownership of the asset to another entity.

On derecognition of a financial asset, the difference between the asset's carrying amount and the sum of consideration received and receivable is recognised in profit or loss.

The Group derecognises financial liabilities when, and only when, the Group's obligations are discharged, cancelled or have expired. The difference between the carrying amount of the financial liability derecognised and the consideration paid and payable is recognised in profit or loss.

4. CRITICAL ACCOUNTING JUDGEMENT

The following is the critical judgement, apart from those involving estimates, that management of the Group has made in the process of applying the Group's accounting policies and that have the most significant effect on the amounts recognised in the consolidated financial statements.

As described in note 3, revenue from Treatment Service is recognised when services are provided. Part of the revenue from Treatment Service is deriving from prepaid treatment packages and these prepaid treatment packages have a valid service period. Prepayments received are initially recorded as deferred revenue in the consolidated statement of financial position, and subsequently recognised as revenue when the services are provided to clients. As represented by the Directors, at their discretion, they may extend the service period and allow clients to enjoy the services under the prepaid treatment packages after the expiry dates as stated on the treatment consent forms. Therefore, the Directors are required to exercise judgment in the application of revenue recognition policies. In such assessment, the Directors consider the general practice and grace period normally adopted by the Group as well as historical customer behaviour and usage pattern of the prepaid treatment packages and the recognition criteria under HKAS 18 "Revenue". For the year ended 31 March 2017, revenue from unused packages in respect of Treatment Service amounting to approximately HK\$784,000 (2016: HK\$565,000) was recognised in the consolidated statement of profit or loss and other comprehensive income.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 March 2017

5. REVENUE

The Group's revenue represents revenue arising from provision of Consultation Service, Prescription and Dispensing Service and Treatment Service during the year, net of discounts and refund.

6. SEGMENT INFORMATION

The Group's operating activities are attributable to a single operating segment focusing on Consultation Service, Prescription and Dispensing Service and Treatment Service. This operating segment has been identified on the basis of internal management reports prepared in accordance with the Group's accounting policies set out in note 3. Dr. Kong and Mr. Lo Kwok Bun, two of the Directors, have been identified as the chief operating decision makers ("CODM"). The CODM review the Group's revenue analysis by services and products in order to assess performance and allocation of resources.

Other than revenue analysis, no operating results or other discrete financial information is available for the assessment of performance and allocation of resources. The CODM review the results of the Group as a whole to make decisions. Accordingly, other than entity wide information, no analysis of this single operating segment is presented.

Revenue from major products and services

	2017	2016
	HK\$'000	HK\$'000
Consultation Service	3,768	3,524
Prescription and Dispensing Service	24,567	26,895
Treatment Service	33,727	29,654
	62,062	60,073

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 March 2017

6. SEGMENT INFORMATION *(Continued)*

Geographical information

The Group's operations are located in Hong Kong. All of the Group's revenue from external customers based on the location of the Group's operations is from Hong Kong.

The geographical location of the Group's non-current assets is situated in Hong Kong based on physical location of assets.

Information about major customers

During each of the years ended 31 March 2017 and 2016, there was no revenue from any customer who individually contributing over 10% of the total revenue of the Group.

7. OTHER INCOME, GAINS AND LOSSES

	2017	2016
	HK\$'000	HK\$'000
Interest income on bank deposits	81	225
Loss on write-off of property, plant and equipment	(15)	(33)
Gain on disposal of property, plant and equipment	23	–
Net foreign exchange gain (loss)	2	(747)
Allowance for bad and doubtful debts	(7)	(15)
Others	26	4
	110	(566)

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 March 2017

8. DIRECTORS' AND CHIEF EXECUTIVE'S EMOLUMENTS

During the year, the emoluments paid or payable to the Directors were as follows:

	Executive Directors				Independent non-executive Directors			Total HK\$'000
	Dr. Kong HK\$'000	Mr. Lo Kwok Bun HK\$'000	Ms. Kong Chung Wai HK\$'000	Ms. Sin Chiu Pik Christine HK\$'000 (note i)	Mr. Chan Cheong Tat HK\$'000	Mr. Lee Ka Lun HK\$'000	Mr. Leung Siu Cheung HK\$'000	
For the year ended 31 March 2017								
Fee	60	60	60	15	180	180	180	735
Other emoluments:								
Salaries	890	1,040	659	895	-	-	-	3,484
Performance bonus (note ii)	1,053	90	58	88	-	-	-	1,289
Share-based payments	-	-	-	-	28	28	28	84
Contributions to retirement benefits scheme	9	18	18	18	-	-	-	63
Total emoluments	2,012	1,208	795	1,016	208	208	208	5,655

	Executive Directors			Independent non-executive Directors			Total HK\$'000	
	Dr. Kong HK\$'000	Mr. Lo Kwok Bun HK\$'000	Ms. Kong Chung Wai HK\$'000	Mr. Chan Cheong Tat HK\$'000	Mr. Lee Ka Lun HK\$'000	Mr. Leung Siu Cheung HK\$'000		
For the year ended 31 March 2016								
Fee	60	60	60	173	173	173	699	
Other emoluments:								
Salaries	-	1,080	765	-	-	-	1,845	
Performance bonus (note iv)	-	140	142	-	-	-	282	
Share-based payments	-	-	-	46	46	46	138	
Contributions to retirement benefits scheme	3	18	18	-	-	-	39	
Total emoluments	63	1,298	985	219	219	219	3,003	

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 March 2017

8. DIRECTORS' AND CHIEF EXECUTIVE'S EMOLUMENTS (Continued)

Notes:

- (i) Ms. Sin Chui Pik Christine was appointed as an executive Director on 1 January 2017.
- (ii) The performance bonuses are determined by reference to the performance of the individual Directors.

Dr. Kong is also the chairman of the Company. Medicskin Laboratories Limited ("**Medicskin**"), a wholly-owned subsidiary of the Company, and Dr. Kong have mutually agreed to terminate the cooperative agreements entered into among, Medicskin, Dr. Kong, and Dr. Kong & Co ("**Dr. Kong Cooperative Agreement**") with effect from 1 January 2017. The details of Dr. Kong Cooperative Agreement are set out in the prospectus issued by the Company dated 12 December 2014. Medicskin and Dr. Kong have entered into an employment agreement to employ Dr. Kong as the chief medical practitioner of the Group with effect from 1 January 2017. Accordingly, his emoluments disclosed above include those for services rendered by him as chief medical practitioner for the period from 1 January 2017 to 31 March 2017. The remaining emoluments of Dr. Kong for the two years ended 31 March 2017 were for his services in connection with the management of the affairs of the Company and the Group. During the period from 1 April 2015 to 31 December 2016, Dr. Kong's sole proprietorship received professional fees for services as a medical practitioner provided to the Group and became one of the five individuals with highest emoluments in the Group during each of the years ended 31 March 2017 and 2016. Accordingly, the fees paid to Dr. Kong's sole proprietorship is included in "employees' emoluments" set out in note 9.

Mr. Lo Kwok Bun is also the chief executive officer of the Company and his emoluments disclosed above include those for services rendered by him as the chief executive officer to manage the affairs of the Company and the Group.

Ms. Kong Chung Wai is also the compliance officer of the Company and her emoluments disclosed above include those for services rendered by her as the compliance officer to manage the affairs of the Company and the Group.

Ms. Sin Chui Pik Christine is also the company secretary and chief financial officer of the Company and her emoluments disclosed above include those for services rendered by her as the company secretary and chief financial officer to manage the affairs of the Company and the Group.

The independent non-executive Directors' emoluments shown above were for their services as Directors of the Company.

During each of the years ended 31 March 2017 and 2016, no emolument was paid by the Group to the Directors as an inducement to join or upon joining the Group or as compensation for loss of office. None of the Directors waived any emoluments during the years.

9. EMPLOYEES' EMOLUMENTS

During the years ended 31 March 2017 and 2016, the five highest paid individuals included Dr. Kong for his service rendered pursuant to the Dr. Kong Cooperation Agreement and Mr. Lo Kwok Bun.

The emoluments of the five highest paid individuals (2016: five) for the year were as follows:

	2017 <i>HK\$'000</i> (note ii)	2016 <i>HK\$'000</i> (note ii)
Salaries, allowances and other benefits	7,342	6,569
Performance related incentive payments:		
Performance bonus (note i)	8,177	7,871
Share-based payments	999	1,048
Contributions to retirement benefits scheme	95	93
	16,613	15,581

Notes:

- (i) The performance related incentive payments are determined by reference to the performance of individuals.
- (ii) The amounts included the total professional fees paid to Dr. Kong's sole proprietorship amounting to approximately HK\$4,028,000 (2016: HK\$5,071,000), which included fixed fee, incentive fee and contributions to retirement benefits scheme of HK\$1,470,000, HK\$2,544,000 and HK\$14,000 (2016: HK\$1,569,000, HK\$3,484,000 and HK\$18,000) respectively.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 March 2017

9. EMPLOYEES' EMOLUMENTS (Continued)

Their emoluments were within the following bands:

	2017	2016
HK\$1,000,001 to HK\$1,500,000	2	2
HK\$1,500,001 to HK\$2,000,000	1	1
HK\$5,000,001 to HK\$5,500,000	–	1
HK\$6,000,001 to HK\$6,500,000	2	1

During each of the years ended 31 March 2017 and 2016, no emolument was paid by the Group to the five highest paid individual as an inducement to join or upon joining the Group or as compensation for loss of office.

10. PROFIT BEFORE TAX

	2017 <i>HK\$'000</i>	2016 <i>HK\$'000</i>
Profit before tax has been arrived at after charging:		
Auditor's remuneration	599	500
Allowance for inventories	29	83
Staff costs		
Directors' emoluments (<i>note 9</i>)	5,655	3,003
Other staff costs		
– salaries, allowance and other benefits	23,850	27,967
– share-based payments (<i>note 24</i>)	1,054	1,093
– contributions to retirement benefits schemes	541	664
	31,100	32,727
<hr/>		
Depreciation of property, plant and equipment		
– owned assets	3,064	2,015

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 March 2017

11. INCOME TAX EXPENSE

	2017 <i>HK\$'000</i>	2016 <i>HK\$'000</i>
Income tax expense comprises:		
Hong Kong Profits Tax		
Current year	1,180	1,250
(Over)underprovision in prior years	(23)	73
	1,157	1,323
Deferred tax charge (<i>note 21</i>)	43	–
	1,200	1,323

Hong Kong Profits Tax is calculated at 16.5% on the estimated assessable profits for the year.

The income tax expense for the year can be reconciled to the profit before tax per the consolidated statement of profit or loss and other comprehensive income as follows:

	2017 <i>HK\$'000</i>	2016 <i>HK\$'000</i>
Profit before tax	4,368	3,677
Tax at Hong Kong Profits Tax rate of 16.5%	721	607
Tax effect of expenses that are not deductible	491	629
Tax effect of income not taxable for tax purpose	(19)	(37)
Tax losses not recognised	81	6
Utilisation of tax losses previously not recognised	(17)	–
(Over)underprovision in prior years	(23)	73
Others	(34)	45
Income tax expense for the year	1,200	1,323

As at 31 March 2017, the Group has unused tax losses of approximately HK\$490,000 (31 March 2016: HK\$105,000) available for offset against future profits. No deferred tax asset has been recognised in respect of the tax losses due to the unpredictability of future profit streams. The tax losses may be carried forward indefinitely.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 March 2017

12. DIVIDENDS

A final dividend in respect of the year ended 31 March 2015 of HK0.25 cent per share, amounting to HK\$1,000,000, was approved by the shareholders in the annual general meeting and distributed by the Company to the shareholders during the year ended 31 March 2016.

On 11 November 2015, a special dividend of HK1.5 cents per share, amounting to HK\$6,000,000, was declared by the Board of Directors (the "Board"). The dividend was distributed by the Company to the shareholders on 10 December 2015.

On 4 March 2016, a special dividend of HK1.5 cents per share, amounting to HK\$6,000,000, was declared by the Board. The Dividend was distributed by the Company to the shareholders on 7 April 2016.

A final dividend of HK0.25 cent per share and a special dividend of HK2.25 cents per share in respect of the year ended 31 March 2016, amounting to HK\$1,000,000 and HK\$9,000,000 respectively, were approved by the shareholders in the annual general meeting and distributed by the Company to the shareholders during the year ended 31 March 2017.

Subsequent to the end of the reporting period, a final dividend of HK0.2 cent per share in respect of the year ended 31 March 2017, amounting to approximately HK\$961,000, has been proposed by the Board and is subject to approval by the shareholders in the forthcoming general meeting.

13. EARNINGS PER SHARE

The calculation of the basic and diluted earnings per share is based on the following data:

	2017 <i>HK\$'000</i>	2016 <i>HK\$'000</i>
Earnings:		
Earnings for the purpose of calculating basic and diluted earnings per share (profit for the year attributable to owners of the Company)	3,168	2,354
	<i>'000</i>	<i>'000</i>
Number of shares:		
Weighted average number of ordinary shares for the purpose of calculating basic earnings per share	434,816	400,000
Effect of diluting potential ordinary shares:		
Share options issued by the Company	265	N/A
Weighted average number of ordinary shares for the purpose of calculating diluted earnings per share	435,081	400,000

In prior year, the computation of earnings per share does not consider the effect of the Company's outstanding share options as the adjusted exercise price of those options were higher than the average market price of shares.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 March 2017

14. PROPERTY, PLANT AND EQUIPMENT

	Leasehold land and building <i>HK\$'000</i>	Leasehold improvements <i>HK\$'000</i>	Office equipment <i>HK\$'000</i>	Medical equipment <i>HK\$'000</i>	Motor vehicles <i>HK\$'000</i>	Total <i>HK\$'000</i>
COST						
At 1 April 2015	–	4,028	1,885	11,521	450	17,884
Additions	–	–	64	2,619	759	3,442
Write-off	–	(33)	(120)	(689)	(450)	(1,292)
At 31 March 2016	–	3,995	1,829	13,451	759	20,034
Additions	48,619	3,350	633	1,034	–	53,636
Write-off	–	(1,483)	(99)	–	–	(1,582)
Disposals	–	(9)	–	(639)	–	(648)
At March 2017	48,619	5,853	2,363	13,846	759	71,440
ACCUMULATED DEPRECIATION						
At 1 April 2015	–	3,673	1,270	8,397	450	13,790
Provided for the year	–	241	214	1,434	126	2,015
Eliminated on write-off	–	(12)	(111)	(686)	(450)	(1,259)
At 31 March 2016	–	3,902	1,373	9,145	126	14,546
Provided for the year	81	1,038	303	1,490	152	3,064
Eliminated on write-off	–	(1,483)	(84)	–	–	(1,567)
Eliminated on disposals	–	(2)	–	(638)	–	(640)
At March 2017	81	3,455	1,592	9,997	278	15,403
CARRYING VALUES						
At 31 March 2017	48,538	2,398	771	3,849	481	56,037
At 31 March 2016	–	93	456	4,306	633	5,488

The above items of property, plant and equipment are depreciated on a straight-line basis after taking into account of their residual values at the following rates per annum:

Leasehold land and building	Over the term of the lease or 50 years
Leasehold improvements	Over the term of the lease
Office equipment	20%
Medical equipment	20%
Motor vehicles	20%

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 March 2017

15. INVENTORIES

	2017 <i>HK\$'000</i>	2016 <i>HK\$'000</i>
Medication and skincare products	2,532	2,269
Treatment consumables	1,167	689
	3,699	2,958

16. TRADE RECEIVABLES

	2017 <i>HK\$'000</i>	2016 <i>HK\$'000</i>
Trade receivables	612	332
Less: Allowance for bad and doubtful debts	(7)	(21)
	605	311

The clients of the Group would usually settle payments by cash, credit cards, Easy Pay System ("EPS") or medical cards. For credit card and EPS payments, the banks will normally settle the amounts a few days after the trade date. Payments by clients using medical cards will normally be settled by the medical card issuing companies within 60 to 90 days from the invoice dates.

The following is an aged analysis of trade receivables net of allowance for bad and doubtful debts presented based on the trade dates for the receivables from the clients settling payments by credit cards and EPS and invoice dates for the receivables from the clients and medical card issuing companies at the end of the reporting period, which approximate the respective revenue recognition dates.

	2017 <i>HK\$'000</i>	2016 <i>HK\$'000</i>
0–30 days	522	278
31–60 days	58	33
61–90 days	25	–
Total	605	311

Before accepting any medical cards, the Group assesses the credit quality of the companies issuing the medical cards by evaluating their historical credit records and defines credit limits by corporates. Recoverability and credit limit of the corporates are reviewed by the Group regularly.

The Group's trade receivables were not past due nor impaired at the end of the reporting period and were due from debtors which do not have historical default of payments.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 March 2017

16. TRADE RECEIVABLES *(Continued)*

Movement in allowance for bad and doubtful debts

	2017 <i>HK\$'000</i>	2016 <i>HK\$'000</i>
Beginning of the year	21	71
Allowance for bad and doubtful debts	7	15
Bad debt written off against allowance	(21)	(65)
<hr/>		
At the end of the year	7	21

During the year ended 31 March 2017, the Group made an allowance of approximately HK\$7,000 (2016: HK\$15,000) in respect of the trade receivables which was past due at the end of the reporting period. Management of the Group considered the related receivables may be impaired due to no settlement after the follow-up actions being taken by the Group to recover the overdue debts and specific allowance is made. In determining the recoverability of a trade receivable, the Group considers any change in credit quality of the trade receivables from the date credit was initially granted up to the end of each reporting period. Management of the Group believes that no further credit provision is required in excess of the allowance for bad and doubtful debts.

17. PLEDGED BANK DEPOSITS AND BANK BALANCES AND CASH

Pledged bank deposits and bank balances and cash comprise cash held by the Group and short-term bank deposits at variable market interest rates with an original maturity of three months or less. For the year ended 31 March 2017, the deposits carried an average effective interest rate of 0.21% (2016: 0.52%) per annum.

As at 31 March 2017, the Group pledged its bank balances of HK\$8,500,000 (2016: HK\$8,500,000) as securities for credit card settlement services provided by a bank to the Group and will be released upon expiry of the relevant services.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 March 2017

18. TRADE PAYABLES

The average credit period on purchase of goods is 30 days. The following is an aged analysis of trade payables presented based on the invoice date at the end of the reporting period:

	2017 <i>HK\$'000</i>	2016 <i>HK\$'000</i>
0–30 days	985	508

19. ACCRUED LIABILITIES

	2017 <i>HK\$'000</i>	2016 <i>HK\$'000</i>
Accrued staff costs	1,979	1,163
Other accruals	1,367	858
	3,346	2,021

20. DEFERRED REVENUE

	2017 <i>HK\$'000</i>	2016 <i>HK\$'000</i>
The movement of deferred revenue is as follows:		
Beginning of the year	7,675	7,395
Receipts from sales of prepaid treatment packages	25,780	15,782
Revenue recognised upon provision of Treatment Service	(18,504)	(14,937)
Revenue recognised from unutilised prepaid treatment packages	(784)	(565)
At the end of the year	14,167	7,675

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 March 2017

21. DEFERRED TAX LIABILITY

The deferred tax liability recognised and movements thereon during the year are as follows:

	Accelerated tax depreciation <i>HK\$'000</i>
At 1 April 2015 and 31 March 2016	127
Charge to profit or loss (<i>note 11</i>)	43
<hr/>	
At 31 March 2017	170

22. SHARE CAPITAL

The share capital at 31 March 2016 and 2017 represented the issued share capital of the Company as detailed below.

	Number of shares	Share capital <i>HK\$'000</i>
Ordinary shares of HK\$0.01 each		
Authorised:		
At 1 April 2015, 31 March 2016 and 2017	1,000,000,000	10,000
<hr/>		
Issued:		
As at 1 April 2015 and 31 March 2016	400,000,000	4,000
Exercise of share options	400,000	4
Issue of shares (<i>note</i>)	80,000,000	800
<hr/>		
At 31 March 2017	480,400,000	4,804

Note: On 25 October 2016, the Company issued 80,000,000 new shares at HK\$0.648 per share for a total gross proceeds of approximately HK\$51,840,000.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 March 2017

23. RETIREMENT BENEFITS PLANS

The Group operates a defined contribution scheme, MPF Scheme, for all qualifying employees in Hong Kong. The MPF Scheme was established under the Mandatory Provident Fund Schemes Ordinance in December 2000. The assets of the scheme are held separately from those of the Group, in funds under the control of trustees.

The Group contributes 5% of relevant payroll costs to the scheme, which contribution is matched by employees. The maximum monthly contribution made by the Group is limited to HK\$1,500 per employee, while an employee can contribute more than HK\$1,500 per month if the employee is willing to do so.

For the year ended 31 March 2017, the total cost of HK\$604,000 (2016: HK\$703,000) charged to the consolidated statement of profit or loss and other comprehensive income represented contributions paid or payable to the MPF Scheme by the Group.

24. SHARE-BASED PAYMENT TRANSACTIONS

Share Option Scheme

The company adopted a share option scheme ("**Share Option Scheme**") on 3 December 2014 to provide incentive and/or to reward eligible persons for their contribution to, and continuing efforts to promote the interest of, the Group. The terms of the Share Option Scheme are in accordance with the provisions of Chapter 23 of the GEM Listing Rules.

At 31 March 2017, the number of shares in respect of which options had been granted and remained outstanding under the Share Option Scheme was 1,600,000 (2016: 2,000,000), representing 0.3% (2016: 0.5%) of the shares of the Company in issue at that date. The total number of shares in respect of which options may be granted under the Share Option Scheme is not permitted to exceed 10% of the shares of the Company in issue at any point in time, without prior approval from the Company's shareholders. The number of shares issued and to be issued in respect of which options granted and may be granted to any individual in any one year is not permitted to exceed 1% of the shares of the Company in issue at any point in time, without prior approval from the Company's shareholders. Options granted to a Director, chief executive or substantial shareholder (or any of their respective associates) of the Company shall not be valid unless it has been approved by the independent non-executive Directors, excluding any independent non-executive Director who is a prospective grantee of the option. Options granted to substantial shareholders or independent non-executive Directors in excess of 0.1% of the Company's share capital or with a value in excess of HK\$5 million must be approved in advance by the Company's shareholders.

An offer of grant of an option may be accepted by an eligible person within the date as specified in the offer issued by the Company, being a date not later than 21 days after (i) the date on which the offer was issued, or (ii) the date on which the conditions (if any) for the offer are satisfied, provided that such date shall not be more than ten years after the date of adoption of the Share Option Scheme. A consideration of HK\$1.00 is payable for each acceptance of grant of option(s). Such consideration shall generally not be refundable. Subject to the other provisions of the Share Option Scheme, an option may be exercised in whole or in part by the grantee (or his personal representatives) at any time before the expiry of the period to be determined and notified by the Board to the grantee which in any event shall not be longer than 10 years commencing on the offer date and expiring on the last day of such 10-year period subject to the provisions for early termination as contained in the Share Option Scheme and provided that the Board may determine the minimum period for which the option has to be held or other restrictions before the exercise of the subscription right attaching thereto.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 March 2017

24. SHARE-BASED PAYMENT TRANSACTIONS *(Continued)*

Share Option Scheme *(Continued)*

The exercise price is determined by the Directors, and will not be less than the higher of (i) the closing price of the Company's shares on the date of grant, (ii) the average closing price of the shares for the five business days immediately preceding the date of grant; and (iii) the nominal value of the Company's share.

A summary of the share options granted under the Share Option Scheme are as follows:

Type of Participants	Grant date	Exercise price per share HK\$	Vesting period	Exercise period	Number of share options				
					As at 1.4.2015	Granted	As at 31.3.2016	Exercised	As at 31.3.2017
Directors	17.08.2015	0.67	17.08.2015– 16.08.2016	17.08.2016– 16.08.2017	–	1,200,000	1,200,000	–	1,200,000
Others	17.08.2015	0.67	17.08.2015– 16.08.2016	17.08.2016– 16.08.2017	–	800,000	800,000	(400,000)	400,000
					–	2,000,000	2,000,000	(400,000)	1,600,000
Exercisable at the end of the year									1,600,000
Weighted average exercise price									HK\$0.67

During the year ended 31 March 2016, an aggregate of 2,000,000 share options were granted to certain Directors and certain doctors of the Group. For the share options granted during the year, the granted share options will vest over 1 year commencing from 17 August 2015 to 16 August 2016.

The estimated fair value of the share options granted on 17 August 2015 was approximately HK\$367,000. The fair value was calculated using the binomial option pricing model.

The inputs into the model were as follows:

Closing share price at date of grant	HK\$0.67
Exercise price	HK\$0.67
Option life	2 years
Expected volatility	49.9%
Dividend yield	0.37%
Risk free interest rate	0.44%

The variables and assumptions used in computing the fair value of the share options are based on the Directors' best estimate. Changes in variables and assumptions may result in changes in the fair value of the options. Expected volatility was determined by historical daily volatilities of the Company's share prices as at the valuation date.

During the year ended 31 March 2017, the Group recognised approximately HK\$139,000 (2016: HK\$228,000) as an expense in the consolidated statement of profit or loss and other comprehensive income in relation to share options granted by the Company.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 March 2017

24. SHARE-BASED PAYMENT TRANSACTIONS *(Continued)*

Share Reward

On 8 August 2012, a service agreement (the "**Service Agreement**") was entered into between Medicskin and Dr. Lam Yee Ming Alice ("**Dr. Lam**") pursuant to which Medicskin employed Dr. Lam as an employee for a term of 5 years commencing from 1 September 2012 and ending on 31 August 2017 (the "**5 Year Term**").

On 20 August 2012, Topline, which was wholly owned by the Group's controlling shareholder, Dr. Kong, had entered into an agreement with Attractive Beauty Limited ("**Attractive Beauty**", a company wholly owned by Dr. Lam) pursuant to which Attractive Beauty acquired two ordinary shares of Tally Scholar Limited ("**Tally Scholar**"), the immediate holding company of the Group prior to the reorganisation of the Group (representing 2% of the then issued share capital of Tally Scholar) for a consideration of HK\$1,600,000 (the "**S&P Agreement**").

Also, Dr. Kong, Topline, Dr. Lam and Attractive Beauty entered into a supplemental agreement on 20 August 2012 (the "**Share Reward Agreement**") and a deed of amendment and restatement on 28 June 2014 (the "**Deed**") which supplemented the above mentioned agreements. The major terms of the Share Reward Agreement as amended and restated pursuant to the Deed are summarised below:

1. In consideration of the satisfactory service by Dr. Lam and Dr. Lam & Co (a sole proprietorship established by Dr. Lam) to Medicskin during the 5 Year Term pursuant to the Service Agreement and the relevant Cooperation Agreement which was entered into among Medicskin, Dr. Lam and Dr. Lam & Co ("**Dr. Lam Cooperation Agreement**"), Dr. Lam shall be entitled to purchase up to 5% of the existing issued share capital of Tally Scholar or the Company (the "**5% Share Entitlement**", calculated on a time proportional basis by reference to the aggregate length of service provided over the 5 Year Term) from Dr. Kong and/or Topline. The purchase of such 5% Share Entitlement by Dr. Lam shall be fully financed by Dr. Kong (the "**Financing**") as follows:
 - (a) subject to the terms relating to the early termination of the Service Agreement or Dr. Lam Cooperation Agreement as discussed below, 2% of the existing issued share capital of Tally Scholar will be transferred to Dr. Lam pursuant to the S&P Agreement, while the related Financing shall become without recourse at the end of the first two years in the 5 Year Term (the "**First 2 Year Term**", that is, on 31 August 2014);
 - (b) subject to the terms relating to the early termination of the Service Agreement or Dr. Lam Cooperation Agreement as discussed below, the next 1% of the existing issued share capital of Tally Scholar or equivalent percent of share capital of the Company will be transferred to Dr. Lam upon Listing or completion of First 2 Year Term, whichever is earlier, while the related Financing shall become without recourse at the end of the anniversary of the First 2 Year Term (that is, on 31 August 2015);
 - (c) the remaining 2% of the existing issued share capital of Tally Scholar or equivalent percent of share capital of the Company will be transferred to Dr. Lam at the completion of the 5 Year Term and the related Financing shall become without recourse at the end of the 5 Year Term (that is, on 31 August 2017);

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 March 2017

24. SHARE-BASED PAYMENT TRANSACTIONS *(Continued)*

2. Pursuant to the terms of Share Reward Agreement as amended and restated pursuant to the Deed, upon the occurrence of early termination of the Service Agreement or Dr. Lam Cooperation Agreement for whatever reason during the 5 Year Term, the proportion of shares transferred to Dr. Lam or Attractive Beauty in advance which Dr. Lam is not entitled to receive as a result of early termination of Service Agreement or Dr. Lam Cooperation Agreement shall be transferred back to Dr. Kong or Topline and the related Financing will also be returned to Dr. Kong.

Hereinafter, the above-mentioned share entitlement is referred to as “Share Reward”.

The following table discloses movements of the Share Reward held by Dr. Lam during the year:

	Outstanding at 1 April 2016	Vested during the year	Outstanding at 31 March 2017
Share Reward	1.42%	1.00%	0.42%
	Outstanding at 1 April 2015	Vested during the year	Outstanding at 31 March 2016
Share Reward	2.42%	1.00%	1.42%

Fair value of the Share Reward granted is expensed over the vesting period, with a corresponding credit to the Group’s capital reserve. For the year ended 31 March 2017, share-based payment expense of approximately HK\$999,000 (2016: HK\$1,003,000) was recognised with a corresponding credit recognised in the Group’s capital reserve.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 March 2017

25. COMMITMENTS Operating Lease Arrangements

The Group as lessee

	2017 <i>HK\$'000</i>	2016 <i>HK\$'000</i>
Minimum lease payments paid under operating leases during the year in respect of rented premises included in other expenses	7,545	5,286

At the end of the reporting period, the Group had commitments for future minimum lease payments under non-cancellable operating leases which fall due as follows:

	2017 <i>HK\$'000</i>	2016 <i>HK\$'000</i>
Within one year	6,761	7,533
In the second to fifth year inclusive	4,496	11,174
	11,257	18,707

Operating lease payments represent rentals payable by the Group for its office premises and Medicskin Centres. Leases are negotiated for the lease terms of one to three years (2016: two to three years) and rentals are fixed throughout the lease terms.

The Group as lessor

A property was acquired by the Group on 24 March 2017. The property has been occupied by a tenant. Vacant possession of the property will be delivered to the Group until the expiration of the existing lease which is expected to end on 21 February 2018 (the "Lease"). The property is classified as property, plant and equipment as the property will be used as a new medical skin care centre of the Group upon expiration of the Lease.

At the end of the reporting period, the Group had contracted with a tenant for the following future minimum lease payments:

	2017 <i>HK\$'000</i>	2016 <i>HK\$'000</i>
Within one year	860	–

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 March 2017

25. COMMITMENTS *(Continued)* Capital commitment

	2017 <i>HK\$'000</i>	2016 <i>HK\$'000</i>
Capital expenditure contracted for but not provided for in the consolidated financial statements in respect of purchase of property, plant and equipment	178	465

26. RELATED PARTY TRANSACTIONS

(a) Transactions

During the year, the Group entered into the following transactions with related parties:

Name of related party	Nature of transactions	2017 <i>HK\$'000</i>	2016 <i>HK\$'000</i>
Dr. Kong	Sales of goods	15	102

During the year ended 31 March 2017, pursuant to the Cooperation Agreement entered into by the Group with Dr. Kong and his sole proprietorship, the total professional fees paid to Dr. Kong's sole proprietorship amounted to approximately HK\$4,028,000 (2016: HK\$5,071,000).

(b) Non-trade balances

As at 31 March 2017 and 2016, the Group had no outstanding balance with related parties.

(c) Compensation of key management personnel

	2017 <i>HK\$'000</i>	2016 <i>HK\$'000</i>
Short-term benefits	6,334	4,769
Post-employment benefits	81	75
	6,415	4,844

The remuneration of Directors and key executives is determined having regard to the performance of the individuals.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 March 2017

27. CAPITAL RISK MANAGEMENT

The Group manages its capital to ensure that entities in the Group will be able to continue as a going concern while maximising the return to shareholders through the optimisation of the debt and equity balance. The Group's overall strategy remains unchanged during the year.

The existing capital structure of the Group consists of equity attributable to owners of the Company, comprising share capital and reserves.

Management of the Group reviews the capital structure on a regular basis. As part of this review, management of the Group considers the cost of capital and the risks associated with each class of capital. Based on recommendations of management of the Group, the Group will balance its overall capital structure through the payment of dividends and new shares issue.

28. FINANCIAL INSTRUMENTS

Categories of financial instruments

	2017 <i>HK\$'000</i>	2016 <i>HK\$'000</i>
<i>Financial assets</i>		
Loans and receivables (including cash and cash equivalents)	40,470	42,383
<hr/>		
<i>Financial liabilities</i>		
Amortised cost	2,352	7,366
<hr/>		

Financial risk management objectives and policies

The Group's major financial instruments include trade receivables, deposits, pledged bank deposits, bank balances and cash, trade payables, accrued liabilities and dividend payable. Details of the financial instruments are disclosed in respective notes. The risks associated with these financial instruments and the policies on how to mitigate these risks are set out below. Management manages and monitors these exposures to ensure appropriate measures are implemented on a timely and effective manner.

Market risk

Interest rate risk

The Group is exposed to cash flow interest rate risk in relation to floating-rate bank balances (see note 17 for details of these bank balances).

The Group currently does not have any interest rate hedging policy. However, management closely monitors its exposure to interest rate risk as a result of change on market interest rate and will consider hedging changes in market interest rates should the need arise.

Management considers the Group's exposure to cash flow interest rate risk of floating-rate bank balances is not significant, hence no sensitivity analysis is presented for the year ended 31 March 2017.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 March 2017

28. FINANCIAL INSTRUMENTS *(Continued)*

Financial risk management objectives and policies *(Continued)*

Credit risk

At the end of the reporting period, the Group's maximum exposure to credit risk which will cause a financial loss to the Group due to failure to discharge obligation by the counterparties is arising from the carrying amount of the respective recognised financial assets as stated in the consolidated statement of financial position.

In order to minimise the credit risk, the Group has monitoring procedures to ensure that follow-up action is taken to recover overdue debts. In addition, the Group reviews the recoverable amount of each individual debt at the end of the reporting periods to ensure that adequate impairment losses are made for irrecoverable amounts. In this regard, the management of the Group considers that the Group's credit risk is significantly reduced.

The credit risk on liquid funds is limited because the counterparties are banks with high credit-ratings assigned by international credit-rating agencies.

Other than the concentration of credit risk on liquid funds which are deposited with several banks with high credit ratings, the Group does not have any other significant concentration of credit risk, with exposure spread over a number of counterparties.

Liquidity risk

In the management of liquidity risk, the Group monitors and maintains a level of cash and cash equivalents deemed adequate by the management to finance the Group's operations and mitigate the effects of fluctuations in cash flows. As at 31 March 2017, the Group had unused banking facilities of HK\$4,000,000 (2016: Nil).

The following table details the Group's remaining contractual maturity for its non-derivative financial liabilities. The table has been drawn up based on the undiscounted cash flows of financial liabilities based on the earliest date on which the Group can be required to pay.

The table includes both interest and principal cash flows. To the extent that interest flows are floating rate, the undiscounted amount is derived from interest rate at the end of the reporting period.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 March 2017

28. FINANCIAL INSTRUMENTS *(Continued)* Financial risk management objectives and policies *(Continued)*

Liquidity risk (Continued)

Liquidity tables

	Weighted average effective interest rate %	Repayable on demand or repayable in 1 to 3 months HK\$'000	Total undiscounted cash flows HK\$'000	Carrying amount at the end of the reporting date HK\$'000
At 31 March 2017				
Non-derivative financial liabilities				
Trade payables	N/A	985	985	985
Accrued liabilities	N/A	1,367	1,367	1,367
		2,352	2,352	2,352
At 31 March 2016				
Non-derivative financial liabilities				
Trade payables	N/A	508	508	508
Accrued liabilities	N/A	858	858	858
Dividend payable	N/A	6,000	6,000	6,000
		7,366	7,366	7,366

Fair value

The fair values of financial assets and financial liabilities have been determined in accordance with generally accepted pricing models based on discounted cash flow analysis.

Management of the Group considers that the carrying amounts of financial assets and financial liabilities recorded at amortised cost in the consolidated financial statements approximate their fair values.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 March 2017

29. PARTICULARS OF SUBSIDIARIES

Particulars of the subsidiaries of the Company at 31 March 2017 and 2016 are as follows:

Name of subsidiary	Date and place of incorporation/establishment	Principal country of operation	Type of legal entity	Issued and fully paid up share capital/registered capital	Proportion of nominal value of share capital/registered capital held by the Company				Principal activities
					Directly		Indirectly		
					2017	2016	2017	2016	
Multiple Profit Enterprise Limited ("Multiple Profit")	1 February 2012 BVI	Hong Kong	BVI business company	Ordinary share US\$1	100%	100%	–	–	Investment holding
Medicskin	12 July 2000 Hong Kong	Hong Kong	Private limited company	Ordinary share HK\$10,000	–	–	100%	100%	Provision of medical skin care services
Beauty Snow Development Limited	1 September 2014 BVI	Hong Kong	BVI business company	Ordinary share US\$1	100%	100%	–	–	Investment holding
Beauty Choice Investment Limited	19 September 2014 Hong Kong	Hong Kong	Private limited company	Ordinary share HK\$1	–	–	100%	100%	Sale of skincare products
Active True Mark Limited	22 April 2015 BVI	Hong Kong	BVI business company	Ordinary share US\$1	100%	100%	–	–	Investment holding
Amazing Queen Limited	30 January 2015 Hong Kong	Hong Kong	Private limited company	Ordinary share HK\$1	–	–	100%	100%	Investment holding
Internet Plus Beauty (Shenzhen) Trading Company Limited ("Internet Plus")	19 August 2015 Shenzhen	People's Republic of China	Wholly foreign owned enterprise	RMB500,000*	–	–	100%	100%	Sale of skincare products
High Rank Ventures Limited	1 July 2015 BVI	Hong Kong	BVI business company	Ordinary share US\$1	100%	100%	–	–	Investment holding
Golden Dickson (HK) Limited	1 November 2016 Hong Kong	Hong Kong	Private limited company	Ordinary share HK\$1	100%	–	–	–	Property holding
Hong Kong Precision and Preventive Medicine Centre Limited	31 March 2017 Hong Kong	Hong Kong	Private limited company	Ordinary share HK\$1	–	–	100%	–	Not yet commence business

* As at 31 March 2017, registered capital of RMB170,000 was paid. The shareholder of Internet Plus is required to pay the registered capital up to RMB500,000 on or before 19 August 2017.

None of the subsidiaries had any debt securities subsisting at the end of the year or at any time during the year.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 March 2017

30. STATEMENT OF FINANCIAL POSITION OF AND RESERVES OF THE COMPANY

Information about the statement of financial position of the Company at the end of the reporting period includes:

	2017 <i>HK\$'000</i>	2016 <i>HK\$'000</i>
Non-current assets		
Unlisted investment in subsidiaries	13,363	2,553
Amounts due from subsidiaries	62,331	–
	<hr/> 75,694	<hr/> 2,553
Current assets		
Deposits and prepayments	202	188
Amounts due from subsidiaries	6,797	43,956
Bank balances	152	50
	<hr/> 7,151	<hr/> 44,194
Current liabilities		
Accrued liabilities	143	107
Dividend payable	–	6,000
	<hr/> 143	<hr/> 6,107
Net current assets	<hr/> 7,008	<hr/> 36,087
Total assets less current liabilities	<hr/> 82,702	<hr/> 40,640
Capital and reserves		
Share capital	4,804	4,000
Reserves	77,898	36,640
Total equity	<hr/> 82,702	<hr/> 40,640

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 March 2017

30. STATEMENT OF FINANCIAL POSITION OF AND RESERVES OF THE COMPANY

(Continued)

Movement in reserves

	Share premium <i>HK\$'000</i>	Retained earnings <i>HK\$'000</i>	Share options reserve <i>HK\$'000</i>	Other reserve <i>HK\$'000</i> <i>(note)</i>	Total <i>HK\$'000</i>
At 1 April 2015	31,670	8,882	–	2,461	43,013
Profit for the year	–	6,399	–	–	6,399
Recognition of equity-settled share-based payments	–	–	228	–	228
Dividends recognised as distribution	–	(13,000)	–	–	(13,000)
At 31 March 2016	31,670	2,281	228	2,461	36,640
Profit for the year	–	1,399	–	–	1,399
Recognition of equity-settled share-based payments	–	–	139	–	139
Exercise of share options	337	–	(73)	–	264
Issue of shares	51,040	–	–	–	51,040
Transaction costs attributable to issue of shares	(1,584)	–	–	–	(1,584)
Dividends recognised as distribution	(9,000)	(1,000)	–	–	(10,000)
At 31 March 2017	72,463	2,680	294	2,461	77,898

Note: The other reserve represents the total equity of Multiple Profit upon the Company became the holding company of Multiple Profit.

FINANCIAL SUMMARY

	For the year ended 31 March				
	2017 <i>HK\$'000</i>	2016 <i>HK\$'000</i>	2015 <i>HK\$'000</i>	2014 <i>HK\$'000</i>	2013 <i>HK\$'000</i>
RESULTS					
Revenue	62,062	60,073	66,738	65,041	51,607
Profit before tax	4,368	3,677	5,884	17,354	17,440
Income tax expenses	(1,200)	(1,323)	(2,556)	(3,617)	(2,908)
Profit for the year attributable to owners of the Company	3,168	2,354	3,328	13,737	14,532
As at 31 March					
	2017 <i>HK\$'000</i>	2016 <i>HK\$'000</i>	2015 <i>HK\$'000</i>	2014 <i>HK\$'000</i>	2013 <i>HK\$'000</i>
ASSETS AND LIABILITIES					
Total assets	101,266	54,099	58,323	39,713	22,779
Total liabilities	18,668	(16,331)	(11,140)	(29,327)	(16,579)
Total equity attributable to owners of the Company	82,598	37,768	47,183	10,386	6,200